

1 PPTC7 antagonizes mitophagy by promoting BNIP3 and NIX degradation via
2 SCF^{FBXL4}
3

4 Giang Thanh Nguyen-Dien^{1,2#}, Brendan Townsend^{1#}, Prajakta Kulkarni^{1#}, Keri-Lyn Kozul^{1#}, Soo
5 Siang Ooi¹, Denaye Eldershaw³, Saroja Weeratunga³, Meihan Liu³, Mathew JK Jones^{4,5}, S Sean
6 Millard^{1,6}, Dominic CH Ng¹, Michele Pagano^{7,8,9}, David Komander¹⁰, Michael Lazarou^{11,12,13}, Brett
7 M Collins^{3*}, Julia K Pagan^{1*}

8 ¹Faculty of Medicine, School of Biomedical Sciences, University of Queensland, Brisbane, QLD,
9 Australia.

10 ²Department of Biotechnology, School of Biotechnology, Viet Nam National University-International
11 University, Ho Chi Minh City, Vietnam

12 ³The University of Queensland, Institute for Molecular Bioscience, Queensland, 4072, Australia.

13 ⁴The University of Queensland Frazer Institute, Faculty of Medicine, The University of Queensland,
14 Brisbane, QLD 4102, Australia

15 ⁵School of Chemistry & Molecular Biosciences, University of Queensland, Brisbane, QLD, 4072,
16 Australia

17 ⁶Clem Jones Centre for Ageing Dementia Research, Queensland Brain Institute, The University of
18 Queensland, Brisbane, QLD 4072, Australia

19 ⁷Department of Biochemistry and Molecular Pharmacology, New York University Grossman School
20 of Medicine, New York, NY 10016, USA

21 ⁸Perlmutter Cancer Center, New York University Grossman School of Medicine, New York, NY
22 10016, USA

23 ⁹Department of Pathology and Lab Medicine, Meyer Cancer Center, Weill Cornell Medicine, New
24 York, NY 10065, USA.

25 ¹⁰Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia.

26 ¹¹Department of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash
27 University, Melbourne, VIC 3068, Australia

28 ¹²Department of Medical Biology, University of Melbourne, Melbourne, VIC 3068, Australia

29
30 [#]Contributed equally

31 *Correspondence: j.pagan@uq.edu.au or b.collins@imb.uq.edu.au

32 Abstract

33 Mitophagy must be carefully regulated to ensure that cells maintain appropriate numbers of
34 functional mitochondria. The SCF^{FBXL4} ubiquitin ligase complex suppresses mitophagy by
35 controlling the degradation of BNIP3 and NIX mitophagy receptors, and *FBXL4* mutations result
36 in mitochondrial disease as a consequence of elevated mitophagy. Here, we reveal that the
37 mitochondrial phosphatase PPTC7 is an essential cofactor for SCF^{FBXL4}-mediated destruction of
38 BNIP3 and NIX, suppressing both basal and induced mitophagy. Disruption of the phosphatase
39 activity of PPTC7 is not required for BNIP3 and NIX turnover. Rather, a pool of PPTC7 on the
40 mitochondrial outer membrane acts as an adaptor linking BNIP3 and NIX to FBXL4, facilitating
41 the turnover of these mitophagy receptors. PPTC7 accumulates on the outer mitochondrial
42 membrane in response to mitophagy induction or the absence of FBXL4, suggesting a
43 homeostatic feedback mechanism that attenuates high levels of mitophagy. We mapped critical
44 residues required for PPTC7-NIX/BNIP3 and PPTC7-FBXL4 interactions and their disruption
45 interferes with both NIX/BNIP3 degradation and mitophagy suppression. Collectively, these
46 findings delineate a complex regulatory mechanism that restricts NIX/BNIP3-induced
47 mitophagy.

48 Introduction

49 Cells eliminate excessive or damaged mitochondria through mitophagy, a selective form of
50 autophagy^{1,2}. The upregulation of mitophagy receptors BNIP3 and NIX on the mitochondrial
51 outer membrane acts as a signal to recruit the autophagosome³⁻⁵, in conditions such as
52 hypoxia⁶⁻⁸, and during the differentiation of specialized cell types like erythrocytes⁹⁻¹¹,
53 neurons^{12,13}, cardiomyocytes^{6,14}, keratinocytes¹⁵, and pro-inflammatory macrophages¹³. It has
54 long been known that BNIP3 and NIX expression is acutely upregulated by transcription^{16,17},
55 however, the molecular understanding of the mechanisms that restrict BNIP3 and NIX
56 expression to prevent excessive mitophagy remains limited.

57 We and others have recently demonstrated that the abundance of BNIP3 and NIX receptors is
58 regulated by the mitochondrially-localised SCF-FBXL4 E3 ubiquitin ligase complex¹⁸⁻²¹. FBXL4
59 is one of 69 F-box proteins that act as interchangeable substrate adaptors for SCF E3 ubiquitin
60 ligase protein complexes. SCF^{FBXL4} localises to the mitochondrial outer membrane and mediates
61 the constitutive ubiquitylation and degradation of BNIP3 and NIX to limit their abundance and
62 thereby suppress mitophagy. The FBXL4 gene is mutated in MTDPS13 mtDNA depletion
63 syndrome, a disease characterised by mitochondrial depletion caused by excessive
64 mitophagy²²⁻²⁴.

65 Little is known regarding the upstream mechanisms that regulate BNIP3 and NIX mitophagy
66 receptor recognition via FBXL4. Phosphorylation or other types of modifications could
67 potentially either enhance or sterically preclude the recognition of BNIP3 and NIX by FBXL4.
68 Alternatively, a cofactor might be required to regulate the assembly of the SCF complex or to
69 bridge the interaction between FBXL4 with BNIP3 and NIX.

70 The PP2C phosphatase PPTC7 (Protein Phosphatase Targeting COQ7) localises to
71 mitochondrial matrix^{25,26}. Despite this localization, it has been identified as an interactor of
72 BNIP3 and NIX²⁷⁻³⁰ and a suppressor of BNIP3 and NIX-dependent mitophagy³¹. Intriguingly,

73 PPTC7 knockout mice exhibit phenotypes reminiscent of FBXL4 KO mice with decreased
74 mitochondria content, increased mitophagy and severe metabolic defects which are associated
75 with perinatal lethality^{21,22,26,32}.

76 Here, we show that PPTC7 is a critical rate-limiting activator of FBXL4-mediated destruction of
77 BNIP3 and NIX and is required to suppress excessive basal and mitophagy induced by
78 pseudohypoxia. We propose that PPTC7 acts as an adaptor to enable the turnover of BNIP3
79 and NIX via the SCF^{FBXL4}. An outer membrane form of PPTC7 interacts with BNIP3 and NIX as
80 well as with FBXL4 and these interactions are required for BNIP3 and NIX turnover and
81 mitophagy suppression. We functionally validate *in silico* predictions of the PPTC7-NIX and
82 PPTC7-FBXL4 interactions to reveal critical residues required for the assembly of the PPTC7-
83 NIX/BNIP3 and PPTC7-FBXL4, and consequently for the turnover of BNIP3 and NIX as well as
84 mitophagy suppression. Together, these findings provide a molecular understanding of the
85 mechanisms that restrict basal and NIX/BNIP3-stimulated mitophagy to prevent excessive
86 mitophagy.

87 **Results**

88 **PPTC7 and FBXL4 cooperate to mediate the turnover of BNIP3 and NIX.**
89 Corresponding with increased mitophagy, PPTC7 deficient cells and tissues have diminished
90 steady-state levels of most mitochondrial proteins, except for BNIP3 and NIX, which instead
91 exhibit a large increase in protein levels^{26,32}. To determine whether PPTC7 regulates BNIP3
92 and NIX expression at the level of protein stability, we generated PPTC7-deficient cell lines
93 using CRISPR/Cas9-mediated gene disruption. Successful knockout was confirmed by
94 immunoblotting using an anti-PPTC7 antibody, which detected bands migrating at 28 kDa, 32
95 kDa and 40 kDa, specifically in parental cell lines but not in PPTC7 KO lines (**Figure 1A, 1D,**
96 **S1B-C**). Cycloheximide chase assays demonstrated that PPTC7 deficiency significantly
97 increased the half-life of BNIP3 and NIX and resulted in the upregulation of BNIP3 and NIX at
98 mitochondria, indicating that PPTC7 is required for BNIP3 and NIX turnover (**Figure 1A-C and**
99 **S1A-B**). To assess whether PPTC7 impacts the transcriptional regulation of BNIP3 and NIX via
100 HIF1 α , we used the HIF1 α inhibitor, echinomycin, to demonstrate that HIF1 α inhibition did not
101 abolish the accumulation of BNIP3 and NIX in PPTC7 KO cells (**Figure S1C**). The abnormally
102 increased levels of BNIP3 and NIX in the PPTC7 KO lines were rescued upon re-expression of
103 wild-type PPTC7 (**Figure 1C**). Collectively, our data suggests that PPTC7 is required for the
104 turnover of BNIP3 and NIX.

105 The turnover of BNIP3 and NIX depends on the SCF^{FBXL4} ubiquitin ligase^{18,19,21}. To investigate
106 whether PPTC7 and FBXL4 operate within the same or separate pathways to regulate BNIP3
107 and NIX turnover, we assessed the stability of BNIP3 and NIX in CRISPR knockout cell lines
108 lacking either PPTC7, FBXL4, or both using a cycloheximide chase assay (**Figure 1D**). Our
109 results demonstrated that the combined deficiency of both PPTC7 and FBXL4 did not lead to
110 further upregulation of either BNIP3 or NIX compared with the individual knockout of PPTC7 or
111 FBXL4, suggesting that FBXL4 and PPTC7 function in a shared pathway (**Figure 1D**).
112 Strikingly, FBXL4 knockout cells displayed a notable increase of the 32 kDa (middle) form of

113 PPTC7 (**Figure 1D**). The 32 kDa form of PPTC7 also accumulated after DFP treatment (**Figure**
114 **S1C**).

115 Immunofluorescence-based complementation assays in FBXL4- and PPTC7-deficient cells
116 showed that the ability of either PPTC7 or FBXL4 to mediate BNIP3 and NIX turnover depends
117 on the presence of the other protein. Rescue of either FBXL4 or PPTC7 into their respective
118 knockout cell lines resulted in the drastic downregulation of NIX levels compared with
119 surrounding untransfected cells (**Figure 1E-F and S1E**). In contrast, FBXL4 overexpression was
120 not able to mediate the downregulation of BNIP3 and NIX in the absence of PPTC7 (**Figure 1E**
121 **and S1D**). Likewise, PPTC7 expression could not promote BNIP3 and NIX downregulation in
122 the absence of FBXL4 (**Figure 1F-G and S1E**). Notably, in these experiments, PPTC7
123 deficiency did not affect the localization or levels of FBXL4 (**Figure 1F and S1D**). Thus, FBXL4
124 and PPTC7 require each other to mediate the downregulation of BNIP3 and NIX.

125 To determine whether PPTC7 levels are rate-limiting for BNIP3 and NIX turnover and
126 consequently for mitophagy suppression, we examined the levels of BNIP3 and NIX in U2OS
127 and 293T cells stably overexpressing PPTC7 (at approximately 100-fold for U2OS and 50-fold
128 for 293T cells). BNIP3 and NIX levels were examined in steady-state conditions or after
129 treatment with DFP, which is an iron chelator and HIF1 α activator known to promote mitophagy
130 via BNIP3 and NIX upregulation^{6,8}. The low levels of BNIP3 and NIX in steady-state conditions
131 made it hard to detect a further decrease in levels upon PPTC7 overexpression in U2OS,
132 however, we found that the overexpression of wild-type PPTC7 resulted in the downregulation
133 of BNIP3 and NIX after DFP treatment in U2OS cells and 293T cells (**Figure S1F-H**). Consistent
134 with its suppression of BNIP3 and NIX protein levels, the overexpression of PPTC7 suppressed
135 DFP-induced mitophagy in U2OS cells (**Figure S1H**). Furthermore, PPTC7 knockout U2OS
136 cells treated with DFP exhibited substantially more mitophagy than either condition alone,
137 indicating that PPTC7 suppresses both basal and DFP-induced mitophagy (**Figure 1H**).
138 Altogether, our experiments indicate that PPTC7 is rate-limiting for FBXL4-mediated BNIP3 and
139 NIX turnover and the associated mitophagy suppression (**Figure 1H**).

140 **A population of PPTC7 localises to the outer mitochondrial membrane and interacts with** 141 **FBXL4 and NIX/BNIP3**

142 PPTC7 has been previously localized to the mitochondrial matrix^{25,33}, whereas BNIP3 and NIX
143 are located at the mitochondrial outer membrane. We sought to clarify the sub-mitochondrial
144 localization of PPTC7 to explore whether PPTC7 is located at both the outer mitochondrial
145 membrane as well as inside the mitochondria. Like other mitochondrial proteins, PPTC7
146 possesses an N-terminal mitochondrial targeting pre-sequence (MTS) that is predicted to be
147 proteolytically cleaved by mitochondrial proteases after import into the mitochondria³⁴, giving
148 rise to a shorter processed form of the protein. Given the molecular weight difference predicted
149 from the removal of the MTS, we posited that the different bands of PPTC7 might represent the
150 precursor form of PPTC7 that has not been imported into mitochondria, and a processed shorter
151 matrix form. To test this hypothesis, we conducted mitochondrial import assays, employing
152 proteinase K to degrade proteins that reside on the outside of the mitochondria (i.e., that are not
153 yet imported) (**Figure 2A**). We observed that the shorter molecular weight form of PPTC7 was
154 resistant to proteinase K suggesting that it is inside the mitochondria. The 40 kDa (upper) form

155 of PPTC7 was also proteinase K resistant, indicating that it likely resides in the matrix.
156 Currently, the nature of the third 40 kDa form of PPTC7 remains unclear, however, we note that
157 we only observe it for endogenous PPTC7 and not exogenous PPTC7.

158 In contrast, we found that the 32 kDa (middle) version of PPTC7, which accumulates in FBXL4-
159 deficient cells, is susceptible to proteinase K, indicating its localization on the mitochondrial
160 outer membrane. Hereafter, we refer to the 32 kDa form of PPTC7 as outer membrane PPTC7
161 (OM-PPTC7), and the 28 kDa form of PPTC7 as inner mitochondrial PPTC7 (matrix-PPTC7).

162 We next explored the relative abundance of the outer/inner forms of PPTC7 in response to
163 different mitophagy activators. In addition to FBXL4 deficiency, conditions known to upregulate
164 BNIP3 and NIX-dependent mitophagy, such as the hypoxia-mimetics DFP and DMOG, resulted
165 in the upregulation of the OM-PPTC7 (**Figure 2B-C and S2A-B**), largely correlating with BNIP3
166 and NIX levels. The greatest upregulation of OM-PPTC7 was observed in DFP-treated, FBXL4-
167 deficient cells, and in this condition, the levels of matrix-PPTC7 were inversely correlated with
168 OM-PPTC7. Note that the non-specific band detected by the PPTC7 antibody disappeared in
169 the conditions associated with the highest mitophagy, which we presume is due to a decrease in
170 mitochondrial content caused by elevated mitophagy. In the same conditions, the decrease in
171 matrix-PPTC7 could theoretically reflect either compromised mitochondrial import of PPTC7 or
172 high levels of mitochondrial degradation through mitophagy or a combination of both and
173 warrants further investigation.

174 Next, we used affinity purification of FLAG-tagged PPTC7 to demonstrate that PPTC7 can
175 robustly interact with both BNIP3 and NIX (**Figure 2E**) and FBXL4 (**Figure 2F**). The interaction
176 between PPTC7 and NIX/BNIP3 was evident in basal conditions, as well as after DFP treatment
177 (**Figure 2E-F**). We also established that FBXL4 is not required for the interaction between
178 PPTC7 and NIX/BNIP3 using FBXL4-deficient cells (**Figure 2F**). In our experimental conditions,
179 it was not possible to conclusively determine whether the interactions between PPTC7 with
180 BNIP3, NIX or FBXL4 changed in response to DFP treatment since they were confounded by
181 the changing levels of proteins after DFP (increased NIX/BNIP3 after DFP, and decreased
182 FBXL4) and require further investigation. Lastly, we tested whether PPTC7 is required for the
183 ability of FBXL4 to bind to SKP1 and CUL1, core members of the SCF complex. FBXL4
184 interacted equally with CUL1 and SKP1 in PPTC7 deficient cells, suggesting that PPTC7 is not
185 required for SCF assembly (**Figure S2C**).

186 To confirm the direct interaction between PPTC7 and NIX/BNIP3 we tested the binding of
187 BNIP3 and NIX synthetic peptide sequences to recombinant PPTC7 by isothermal titration
188 calorimetry (ITC). We first tested the functionality of PPTC7 by measuring the association of the
189 PPTC7 active site with divalent cations, observing binding of both Mg^{2+} and Mn^{2+} , but with a
190 much higher affinity for Mn^{2+} (**Figure S2E; Supplementary Table 1**) in line with the previous
191 demonstration of Mn^{2+} -dependent activity²⁵. Subsequently, we found that both BNIP3 and NIX
192 peptides bound to PPTC7 directly, with similar although modest affinities (K_d) of 20 and 37 μM
193 respectively (**Figure S2F; Supplementary Table 2**).

194 Since BNIP3 and NIX demonstrated binding to PPTC7, but little to no binding with FBXL4 in our
195 experimental conditions (**Figure S2B**), this led us to speculate that PPTC7 might serve as a

bridge or scaffold between FBXL4 and NIX/BNIP3. To examine this at the molecular level, we modelled the interactions between PPTC7, FBXL4 and NIX/BNIP3 using AlphaFold2 (**Figure 2F and S2D-E**). Predictions of pairwise complexes or all three proteins together resulted in identical structural models. Alphafold2 predicts a high confidence interaction between FBXL4 and one surface of PPTC7, while a conserved sequence found in both BNIP3 and NIX associates with the active site of PPTC7. A conserved and negatively charged pocket formed between FBXL4's N-terminal discoidin domain and C-terminal LRR domains surrounds PPTC7's residues E125-K130 (**Figure 2F-G and S2G-H**). The binding of BNIP3 and NIX involves a highly extended peptide sequence of ~25 residues including the distal end of BNIP3/NIX's non-canonical BH3 domains, centred on a highly conserved sequence, which we hereafter refer to as the SRPE sequence (encompassing residues 187-190 and 146-149 and in BNIP3 and NIX respectively). The conserved Ser sidechain is predicted to bind the catalytic pocket, precisely where a phosphorylated substrate would be expected to interact. These structural predictions are consistent with PPTC7 serving to position NIX/BNIP3 to be substrates of the SCF^{FBXL4} E3 complex.

211 **Disruption of the catalytic activity of PPTC7 does not affect BNIP3 and NIX turnover in 212 basal conditions.**

213 BNIP3 and NIX are known to be phosphoproteins, and PPTC7 knockout systems have shown
214 elevated phosphorylation at specific residues on BNIP3 and NIX³², albeit not within the regions
215 of BNIP3 and NIX predicted to interact with PPTC7. Specifically, interrogation of existing
216 phosphorylation databases finds no evidence of phosphorylation on NIX's Ser146 or BNIP3's
217 Ser187, which are situated within the PPTC7 active site. Furthermore, phospho-proteomic
218 analysis of affinity-purified BNIP3 from PPTC7 KO cells did not detect phosphorylation at
219 Ser187 (**Supplementary Table 3**).

220 To determine whether the phosphatase activity of PPTC7 is required for BNIP3 and NIX
221 turnover, we engineered mutant versions of PPTC7 predicted to have disrupted phosphatase
222 activity. This involved mutating the active site residues, which were identified through a
223 comparison of the AlphaFold2 prediction of PPTC7 (ID: AF-Q8NI37-F1) with the crystal
224 structure of the similar PPM/PP2C family homologue photosystem II (PSII) core phosphatase
225 (PBCP) (PDB ID: 6AE9)³⁵. Specifically, we substituted the metal-binding aspartate residues at
226 positions Asp78, Asp233, and Asp290 in PPTC7 (**Figure 3A and S3A**). We found that PPTC7
227 mutants in which Asp78 and Asp233 were mutated to alanine (PPTC7-D78A and PPTC7-
228 D223A) were unable to rescue BNIP3 and NIX turnover when complemented into PPTC7-
229 deficient cells (**Figure S3B-C**). However, these mutations also significantly reduced the binding
230 of PPTC7 to BNIP3 and NIX (**Figure S3D**), either due to the loss of metal-binding required to
231 coordinate the Ser sidechain in the SRPE NIX/BNIP3 binding sequences, or possibly due to
232 conformational rearrangements. Thus, it was not possible to ascertain if the lack of turnover was
233 due to a lack of phosphatase activity or reduced binding to NIX/BNIP3.

234 To preserve the metal binding activity of PPTC7 and thus the interaction between PPTC7 and
235 NIX/BNIP3, we next substituted the polar aspartate residues with alternate polar asparagine
236 residues (D78N, D223N, or D290N). This change preserved partial binding between PPTC7 and

237 NIX/BNIP3, with the PPTC7-D290N variant displaying the greatest binding compared with wild-
238 type PPTC7 (**Figure 3B**).

239 To determine if the catalytic activity of PPTC7 is important for BNIP3 and NIX degradation, we
240 expressed PPTC7-wildtype or PPTC7-aspartate to asparagine active site mutants in PPTC7 KO
241 cells. Complementation assays demonstrated that PPTC7-D290N can fully rescue the turnover
242 of BNIP3 and NIX as well as wild-type PPTC7 (**Figure 3C-D**), with partial rescue observed for
243 PPTC7-D78N and PPTC7-D223N. We confirmed that PPTC7-D290N had compromised
244 catalytic activity compared with PPTC7-wildtype by assessing the BNIP3 phospho-migration
245 shift, finding purified wild-type PPTC7 could dephosphorylate BNIP3 however PPTC7-D290N
246 could not (**Figure 3E**). PPTC7-D290N was also confirmed to be catalytically defective using
247 pNPP phosphatase assays (**Figure 3F**). Our data demonstrates that although BNIP3 (and likely
248 NIX) can be dephosphorylated by PPTC7 (**Figure 3E**), the FBXL4-mediated degradation of
249 BNIP3 and NIX is still mediated by the catalytically defective PPTC7, suggesting that the
250 turnover of PPTC7 depends on its presence, but not its full activity.

251 **NIX/BNIP3-PPTC7 interactions are critical for NIX/BNIP3 turnover and mitophagy
252 suppression.**

253 To further test the significance of the interaction between NIX/BNIP3 and PPTC7, we sought to
254 disrupt the interaction between NIX/BNIP3 and PPTC7. Based on our models of the PPTC7
255 complex with either BNIP3 or NIX using Alphafold2³⁶, Tyr179 and Asn181 in PPTC7 were
256 predicted to be critical residues required for binding of NIX/BNIP3 without affecting the PPTC7
257 active site (**Figure 3A**). On the NIX/BNIP3 interface, Trp144 in the BH3 domain, and a highly
258 conserved SRPE region in NIX/BNIP3 were predicted to interact with PPTC7's active site
259 (residues 187-190 in BNIP3 and 146-149 and NIX) (**Figure 3A and 3D**).

260 To test the Alphafold2 prediction, we made the following mutations in PPTC7: Y179D to disrupt
261 the interface with NIX/BNIP3 and N181E to disrupt the local pocket around the phosphoserine-
262 binding catalytic site (**Figure 4A**). First, we tested whether these mutants lose binding to
263 NIX/BNIP3 using an anti-FLAG affinity pulldown assay. Our results demonstrated that PPTC7-
264 Y179D and PPTC7-N181E have reduced binding to both BNIP3 and NIX (**Figure 4B**), indicating
265 that Tyr179 and Asn181 residues are important for the interaction with NIX/BNIP3. In contrast,
266 Gln128 and Lys130 lie in the putative FBXL4 binding site, and Q128R and K130E mutations in
267 PPTC7 did not affect NIX/BNIP3 binding, as predicted (**Figure 4B**), acting as controls for testing
268 NIX/BNIP3 interactions.

269 Secondly, we tested whether the disruption of PPTC7's ability to interact with NIX/BNIP3
270 disrupted the ability of PPTC7 to mediate NIX/BNIP3 turnover. As hypothesised, the loss of
271 PPTC7's interaction with BNIP3 and NIX resulted in a loss of its ability to mediate BNIP3 and
272 NIX turnover (**Figure 4C**). We performed rescue assays in PPTC7 KO cell lines using either
273 wild-type PPTC7 or the variants in PPTC7 with defective binding to NIX/BNIP3: PPTC7-Y179D
274 and PPTC7-N181E. We found that, unlike wild-type PPTC7 which reduced the elevated BNIP3
275 and NIX levels, PPTC7-Y179D and PPTC7-N181E displayed elevated NIX/BNIP3 compared
276 with wild-type PTC7 as assessed using a cycloheximide chase assay (**Figure 4C-D**). The
277 mutants localised to the mitochondria as expected (**Figure 4D**).

278 To functionally validate the regions on BNIP3 and NIX required for their interaction with PPTC7,
279 a series of NIX or BNIP3 mutation constructs were expressed in NIX/BNIP3 double knockout
280 cells: NIX-W144D, NIX-Δ140-150, NIX-R147D, and triple substitutions of R-P-E₍₁₄₇₋₁₄₉₎ to either
281 alanines (RPE-AAA) or aspartic acid and alanines (RPE-DAA). We performed FLAG affinity
282 purification assays in HeLa Flp-In NIX/BNIP3 double KO cells co-expressing doxycycline-
283 inducible FLAG-tagged wild-type NIX or NIX mutants along with HA-tagged PPTC7 (**Figure 4E**
284 and **S4C**). Indeed, we found that despite the lower levels of wild-type NIX, only wild-type NIX
285 was able to bind to PPTC7 (**Figure 4E and S4C**), whereas NIX-W144D, NIX-RPE/AAA, NIX-
286 RPE/DAA and NIX-Δ140-150 were not. Fitting with the hypothesis that the interaction occurs at
287 the outer membrane, the OM-form of PPTC7 bound preferentially to NIX. The expression of
288 PPTC7-WT promoted the downregulation of wild-type NIX, but not the PPTC7-binding NIX
289 variants, supporting the model that the binding of PPTC7 to NIX is required for its degradation.
290 Therefore, the region surrounding the SRPE domain in NIX is required for functional interaction
291 with PPTC7.

292 Having demonstrated that NIX's SRPE and nearby residues are important for PPTC7 binding,
293 we next assessed their stability. Supporting the Alphafold2 model, each of the NIX mutants
294 displayed higher expression and longer half-lives than wild-type NIX (**Figure 4F and S4D**).
295 These results suggest that the PPTC7-binding region in NIX plays an important role in its
296 turnover.

297 Since elevated levels of BNIP3 and NIX correlate with increased mitophagy, we tested the
298 hypothesis that the expression of the PPTC7-resistant hyper-stable NIX mutants would result in
299 elevated mitophagy using a mtKeima assay (**Figure 4H and S4D**). In our conditions, the
300 expression of wild-type NIX does not induce mitophagy since it is expressed at low levels,
301 enabling a direct comparison of how stabilizing NIX by preventing its interaction with PPTC7
302 influences mitophagy. We expressed NIX-RPE/AAA, NIX-RPE/DAA and NIX-W144D in mt-
303 Keima-expressing and compared the induction of mitophagy to that induced by wild-type NIX
304 (**Figure 4G and S4E**). We found that the expression of NIX-RPE/AAA and RPE/DAA resulted in
305 substantially elevated mitophagy in cells compared with wildtype NIX, indicating that the
306 stabilisation of NIX due to loss of its binding to PPTC7 results in hyperactivation of mitophagy.

307 Taken together, these results validate the Alphafold2 modelling and demonstrate the
308 importance of the BH3-SRPE region of NIX/BNIP3 and the Tyr179 and Asn181 residues of
309 PPTC7 in NIX-PPTC7 binding. Furthermore, the results demonstrate that PPTC7 interaction is
310 important for NIX/BNIP3 turnover and mitophagy suppression.

311 **The FBXL4-PPTC7 interaction is critical for mitophagy receptor turnover and mitophagy 312 suppression.**

313 To test whether PPTC7's interaction with FBXL4 is required for BNIP3 and NIX turnover, we
314 proceeded to explore PPTC7's interaction with FBXL4 using AlphaFold2 modelling. The
315 predictions indicated that FBXL4's Met71 and Arg544 are important for interaction with PPTC7
316 (**Figure 5A**), therefore we generated the following FBXL4 mutants to test binding to PPTC7:
317 FBXL4-M71E, FBXL4-R544E or FBXL4-M71E/R544E. Consistent with the structural models, we
318 found that FBXL4 mutants displayed weaker binding to PPTC7 than wild-type FBXL4, with the

319 greatest reduction in binding to PPTC7 observed for FBXL4-M71E/R544E (**Figure 5B**). The
320 binding of BNIP3 and NIX to PPTC7 was greatly increased in cells expressing the FBXL4
321 mutants that were unable to bind to PPTC7 (FBXL4-M71E, M544E, and M71E/R544E). This
322 increase in binding is likely due to their increased levels, rather than any increase in affinity
323 although our data does not rule this out. However, the result confirms that the interaction
324 between FBXL4 and PPTC7 is not required for the interaction between PPTC7 and NIX/BNIP3
325 (**Figure 5B**).

326 We next assessed the functional significance of this interface by assessing whether the loss of
327 the binding between FBXL4 and PPTC7 affects the ability of FBXL4 to mediate the turnover of
328 BNIP3 and NIX. Rescue assays were performed in FBXL4 KO cells expressing FBXL4 wild-
329 type, FBXL4-M71E, FBXL4-E544E, or FBXL4-M71E/R544E and the stability of BNIP3 and NIX
330 were assessed using a cycloheximide chase assay (**Figure 5C**). We found that the double
331 mutant of FBXL4-M71E/R544E was unable to reduce the stability of BNIP3 and NIX to the same
332 level as FBXL4-wild-type. Similar to FBXL4 deficiency, the outer-membrane form of PPTC7 was
333 also stabilized in cells expressing FBXL4 variants unable to bind to PPTC7. Notably, despite
334 their reduced ability to downregulate BNIP3 and NIX (**Figure 5B-C**), the FBXL4 variants
335 localized, like wild-type FBXL4, to mitochondria (**Figure 5D**).

336 Finally, we validated that these residues are important for the ability of FBXL4 to suppress
337 mitophagy, finding that FBXL4-M71E/R544E was also less effective at suppressing mitophagy
338 when reconstituted into FBXL4-deficient cells, correlating with increased BNIP3 and NIX levels
339 in cells expressing the variants compared with wild-type FBXL4 (**Figure 5E**). In all, these
340 results suggest that the interaction with PPTC7 is required for FBXL4 to regulate NIX/BNIP3
341 turnover and for the ability of FBXL4 to suppress mitophagy.

342 **Discussion**

343 In this study, we provide evidence that PPTC7 facilitates the SCF^{FBXL4}-mediated turnover of
344 BNIP3 and NIX. Our findings suggest that PPTC7 is a critical rate-limiting factor determining the
345 amount of BNIP3 and NIX turnover and that it operates directly at the outer mitochondrial
346 membrane by interacting with NIX/BNIP3 as well as with FBXL4, rather than employing an
347 indirect mechanism.

348 PPTC7 accumulates at the mitochondrial outer membrane in response to pseudohypoxia and
349 other conditions associated with elevated BNIP3/NIX-mediated mitophagy. The observed
350 increase in outer-membrane PPTC7 in response to high mitophagy suggests a potential
351 homeostatic feedback mechanism to limit excessive mitophagy. However, it remains
352 incompletely understood how PPTC7's localisation to the outer membrane is regulated. PPTC7
353 may be co-regulated with BNIP3 and NIX by FBXL4-mediated turnover. Alternatively,
354 homeostasis may be achieved by modulating the rate of PPTC7 import into mitochondria. The
355 accumulation of outer membrane PPTC7 may be a consequence of defective protein import,
356 active retention mechanisms, or a combination of these possibilities. It also remains an open
357 question whether this regulation might occur in a localized manner, perhaps targeting specific
358 mitochondria.

359 While we were preparing this manuscript, a study by Sun and colleagues was published, which
360 contains highly complementary findings to ours about the regulation of BNIP3 and NIX through
361 the FBXL4 and PPTC7³⁷. Their findings, akin to ours, show that PPTC7 acts as a critical and
362 limiting factor in governing the FBXL4-mediated degradation of BNIP3 and NIX. Additionally,
363 both studies highlight the dual localisation of PPTC7 to the matrix as well as the mitochondria
364 outer membrane to enable its interaction with BNIP3 and NIX. Similarly, using different
365 approaches to inhibit PPTC7, Sun *et al* suggest that the full catalytic activity of PPTC7 is not
366 required for the turnover of BNIP3 and NIX, paralleling our observations. Sun *et al* additionally
367 present elegant physiological data suggesting that the upregulation of PPTC7 in the context of
368 liver during fasting conditions is required to maintain mitochondrial numbers in this organ. An
369 interesting area needing further clarification in the future is the working model for how PPTC7
370 scaffolds the essential interactions between FBXL4 and NIX/BNIP3 and/or the SCF complex
371 itself. In this regard, our data diverges from the working model of Sun *et al*, suggesting that
372 rather than promoting SCF complex assembly through CUL1 recruitment, PPTC7 acts as an
373 adaptor between FBXL4 and BNIP3. Further investigation incorporating structural and
374 mechanistic data is required to reconcile these interesting findings. Altogether, the considerable
375 overlap between our findings and those of Sun and colleagues underscores the indispensable
376 role of the PPTC7-FBXL4 axis in suppressing mitophagy.

377 In silico modelling suggests that PPTC7 bridges the interaction of BNIP3 and NIX with FBXL4,
378 enabling the effective positioning of the SCF complex for productive ubiquitylation of BNIP3/
379 NIX. This conclusion is further supported by functional assays, which demonstrate that
380 disrupting the interactions between NIX and PPTC7, as well as between FBXL4 and PPTC7,
381 results in the stabilization of BNIP3 and NIX, leading to increased basal mitophagy. Our results
382 suggest that PPTC7 binds to directly to substrates BNIP3 and NIX, rather than the SCF
383 components. The PPTC7 scaffold function we propose resembles the function of the CKS1
384 accessory factor, which plays a critical role in facilitating the interaction between FBXL1 (also
385 known as SKP2) and its substrate, the cyclin-dependent kinase (Cdk) inhibitor p27³⁸.

386 We note that we have not yet investigated whether certain conditions modulate FBXL4-PPTC7-
387 NIX/BNIP3 interactions. These could be local signalling events, like oxidative stress, or global
388 conditions like starvation. Moreover, although our structure-function analyses support the
389 significance of individual structural interfaces, it remains possible that PPTC7 may interact in a
390 mutually exclusive manner with either NIX/BNIP3 or FBXL4 since we have not provided
391 experimental evidence for the existence of a trimeric complex.

392 Future research should address the importance of PPTC7's catalytic activity in BNIP3 and NIX
393 degradation. Phosphorylation of BNIP3 and NIX has been shown to influence their stability
394 and/or their capacity to promote mitophagy^{5,39,40 41,42}, suggesting that dephosphorylation may
395 be required for their turnover and/or mitophagy suppression. Although our data suggest that
396 PPTC7's catalytic activity is largely dispensable for BNIP3 and NIX degradation, it remains
397 possible that small amounts of catalytic activity from the PPTC7-D290N mutant are sufficient for
398 turnover of BNIP3 and NIX in basal conditions. Alternatively, the catalytic activity of PPTC7 may
399 be more important in certain conditions with elevated BNIP3 and NIX, such as during hypoxia or
400 iron chelation. PPTC7-mediated dephosphorylation may promote critical interactions required


401 for FBXL4 to mediate BNIP3 and NIX turnover. For instance, another F-box protein, FBXL2,
402 interacts with the PTPL1 phosphatase, which dephosphorylates p85 β on Tyr-655, thereby
403 promoting p85 β binding to FBXL2 and subsequent degradation⁴³. Both BNIP3 and NIX contain
404 a serine residue (Serine146 in NIX and Ser187 in BNIP3) that directly interacts with the active
405 site of PPTC7, where a phosphorylated substrate would typically bind. However, it is important
406 to note that we have not yet found evidence for phosphorylation of this serine residue in existing
407 literature or our phosphor-proteomic studies. Lastly, whether the catalytic activity or levels of
408 PPTC7 and/or SCF-FBXL4 are regulated in response to environmental conditions remains a
409 topic for further exploration.

410 On the other hand, if the enzymatic activity of PPTC7 is indeed dispensable for its regulation of
411 NIX and BNIP3 turnover, this raises the question of the actual role of its catalytic activity. It is
412 possible that PPTC7-dependent dephosphorylation of BNIP3 and NIX, or FBXL4—or perhaps
413 regulatory proteins such as mitochondrial import proteins²⁶—could serve a distinct role on the
414 outer membrane to suppress mitophagy. Gaining insights into the kinases that counteract
415 PPTC7's function will be crucial for understanding how it contributes to the homeostatic
416 regulation of mitophagy.

417 **Figure Legends**

418 **Figure 1. PPTC7 and FBXL4 coordinate the turnover of BNIP3 and NIX mitophagy receptors to suppress**

419 mitophagy.



420

421 **A. BNIP3 and NIX are stabilized in PPTC7-deficient U2OS cells. CRISPR-CAS9 was used**

422 **to knockout PPTC7 in U2OS cells. Cells were treated with cycloheximide for the indicated**

423 **times before immunoblotting as indicated. The red asterisks indicate PPTC7 specific**

424 **bands at 28 kDa, 32 kDa, and 40 kDa. ns=non-specific band at ~36 kDa.**

425 B. Immunofluorescence staining of BNIP3 and NIX demonstrating increased levels of both
426 proteins at mitochondria in PPTC7 deficient cells U2OS cells. Cells were stained with
427 BNIP3 or NIX (in green) and counterstained with MitoTracker (in magenta). Scale bar of
428 main = 20 microns. Scale bar of inset = 1 micron.

429 C. *Re-expression of PPTC7 into PPTC7-deficient cells reduces the stability of BNIP3 and*
430 *NIX.* PPTC7-HA was transduced into PPTC7-deficient 293T cells. The half-lives of BNIP3
431 and NIX were analysed by immunoblotting after a cycloheximide chase.

432 D. *Targeting PPTC7 and FBXL4 simultaneously does not further increase BNIP3 and NIX*
433 *levels or stability.* PPTC7 was sequentially knocked out of previously generated FBXL4-
434 deficient cells to make the double knockout of PPTC7 and FBXL4 (dKO FBXL4/PPTC7).
435 The 32 kDa band of PPTC7 was upregulated in the FBXL4 KO cells.


436 E. *FBXL4 requires PPTC7 to mediate the downregulation of NIX.* FBXL4-HA was
437 transduced in parental, FBXL4 KO, PPTC7 KO, and FBXL4/PPTC7 dKO cells. NIX
438 protein levels (magenta) were monitored in FBXL4(HA) expressing cells (green). Full
439 figure in Appendix 1A. Scale bar = 20 microns.

440 F. *PPTC7 requires FBXL4 to mediate the downregulation of NIX.* PPTC7-HA was
441 expressed in parental, FBXL4 KO, PPTC7 KO, and FBXL4/PPTC7 dKO cells. NIX protein
442 levels (magenta) were monitored in PPTC7(HA) expressing cells (green). To correlate
443 NIX levels with PPTC7 expression, PPTC7 expressing cells (green) are outlined in
444 orange dotted lines. Full figure in Appendix 1B. Scale bar = 20 microns.

445 G. *FBXL4 is required for the PPTC7-mediated downregulation of BNIP3 and NIX.*
446 PPTC7(HA) was transduced into U2OS, FBXL4 KO or PPTC7 KO cells and the half-lives
447 of BNIP3 and NIX were monitored by immunoblotting. PPTC7(HA) rescue into PPTC7
448 KO cells causes a reduction of BNIP3 and NIX. In contrast, the expression of PPTC7(HA)
449 into FBXL4 KO cells does not cause a reduction in either NIX or BNIP3.

450 H. *PPTC7-deficiency leads to elevated mitophagy in basal conditions and after DFP*
451 *treatment.* U2OS mtKeima PPTC7 KO cells were treated with DFP for 24 hours. Emission
452 signals at neutral pH were obtained after excitation with the 458 nm laser (green), and
453 emission signals at acidic pH were obtained after excitation with the 458 nm laser 561 nm
454 laser (magenta). Mitophagy is represented as the ratio of mt-Keima 561 nm fluorescence
455 intensity to mt-Keima 458 nm fluorescence intensity for individual cells normalised to the
456 mean of the untreated condition. > 70 cells per condition were analysed. P values were
457 derived from a non-parametric one-way ANOVA test. ***p<0.0001. Source data
458 available. Scale bar = 20 microns.

459 *Supplementary Figure 1. PPTC7 is required for the FBXL4-mediated destabilization of NIX/BNIP3*



460

461 A. *Distinct guide RNAs targeting PPTC7 result in BNIP3 and NIX upregulation.* Cells were
462 transfected PPTC7 guide 1 (G1) or guide 2 (G2). The red asterisks indicate PPTC7
463 specific bands and 28 kDa, 32 kDa, and 40 kDa. ns=non-specific band at ~36 kDa.

464 B. *BNIP3 and NIX are stabilized in PPTC7-deficient 293T cells.* Cells were treated with
465 cycloheximide for the indicated times before immunoblotting as indicated.

466 C. *Inhibition of HIF1 α with echinomycin does not prevent the accumulation of BNIP3 and
467 NIX in PPTC7-deficient cells.* U2OS cells or PPTC7-KO cells were treated with
468 echinomycin for 24 hours. Echinomycin completely prevented the DFP-induced
469 upregulation of BNIP3 and NIX, but only partially prevented the accumulation of BNIP3
470 and NIX in PPTC7 KO cells. DFP induces the 32 kDa form of PPTC7.

471 D. *FBXL4 requires PPTC7 for its ability to promote BNIP3 and NIX turnover.* FBXL4-HA
472 was expressed in parental, FBXL4 KO, PPTC7 KO, and FBXL4/PPTC7 dKO cells.
473 BNIP3 and NIX protein levels were monitored by Western blotting in response to FBXL4
474 expression.

475 E. *PPTC7-mediated downregulation of BNIP3 and NIX does not occur in FBXL4-deficient*
476 *cells.* PPTC7-FLAG was transfected into either PPTC7 KO or FBXL4 KO cells. Cells
477 were fixed and stained for FLAG(PPTC7) (green) and either NIX or BNIP3 (magenta).
478 The orange dotted line surrounds the cells that have been transfected with PPTC7.

479 F. *PPTC7(HA) overexpression causes the downregulation of BNIP3 and NIX in U2OS and*
480 *293T cells in basal conditions and after DFP treatment.* PPTC7(HA) was transduced into
481 U2OS or 293T cells and the levels of BNIP3 and NIX were monitored by immunoblotting.


482 G. *PPTC7 overexpression results in the destabilization of BNIP3 and NIX in basal*
483 *conditions as well as after DFP treatment.* U2OS cells or U2OS cells stably transfected
484 with PPTC7(HA) were treated with DFP for 24 hours. Cells were subjected to
485 cycloheximide chase. s.e. = shorter exposure.

486 H. *PPTC7 overexpression suppresses DFP-induced mitophagy.* Mitophagy was assessed
487 U2OS mtKeima cells or U2OS mtKeima cells overexpressing PPTC7(HA) in the
488 presence or absence of DFP. Emission signals at neutral pH were obtained after
489 excitation with the 458 nm laser (green), and emission signals at acidic pH were
490 obtained after excitation with the 458 nm laser 561 nm laser (magenta). Mitophagy is
491 represented as the ratio of mt-Keima 561 nm fluorescence intensity divided by mt-Keima
492 458 nm fluorescence intensity for individual cells normalised to the mean of the
493 untreated U2OS cells. Translucent grey dots represent measurements from individual
494 cells. Coloured circles represent the mean ratio from independent experiments. The
495 centre lines and bars represent the mean of the independent replicates +/- standard
496 deviation. P values were calculated based on the mean values using a one-way ANOVA
497 (*P<0.05, **P<0.005, ***P<0.001, ****P<0.0001). N=3.

498

499

500 **Figure 2. A population of PPTC7 localises to the mitochondria outer membrane to enable its**
 501 **interaction with BNIP3 and NIX and FBXL4**



502

503 **A. The 32 kDa migrating form of PPTC7 is located on the mitochondrial outer membrane,**
 504 **while the lower migrating form of PPTC7 resides in the matrix. Mitochondria were**
 505 **isolated from parental U2OS, FBXL4 KO, PPTC7 KO or PPTC7/FBXL4 dKO cells. The**
 506 **submitochondrial localisation of PPTC7 was determined by proteinase K treatment,**

507 which degrades proteins that are not imported within the mitochondria, i.e., outer
508 membrane proteins. The red asterisks indicate PPTC7-specific bands. The arrow points
509 to the non-specific band at 36 kDa which is enriched in mitochondria.

510 B. *The outer membrane form of PPTC7 is induced by DFP treatment and in FBXL4*
511 *deficient cells.* U2OS cells or FBXL4 KO cells were treated with DFP for the indicated
512 times.

513 C. Analysis of the stability of the outer membrane form of PPTC7 in response to FBXL4
514 deficiency. FBXL4 KO cells and FBXL4 KO cells expressing FBXL4(HA) were subjected
515 to cycloheximide chase assay in the presence or absence of DFP. DFP treatment and
516 FBXL4 deficiency both extended the half-live of OM-PPTC7.


517 D. *PPTC7 interacts with NIX/BNIP3 in basal conditions in an FBXL4-independent manner.*
518 U2OS cells or FBXL4 KO cells were transfected with PPTC7-FLAG and treated with
519 DFP for 24 hours. Cell lysates were immunoprecipitated with anti-FLAG beads, and the
520 immuno-precipitates were analysed by immunoblotting as indicated. WCL = whole cell
521 lysates.

522 E. *PPTC7 interacts with FBXL4.* As in E, including FBXL4 KO cells rescued with HA-tagged
523 FBXL4 WT.

524 F. *AlphaFold2 multimer model of FBXL4, PPTC7 and NIX.* See also Figures S2F-G.

525 G. The FBXL4 pocket is coloured to indicate surface sequence conservation or surface
526 electrostatics using Consurf or Protein-Sol Patches server.

527 *Supplementary Figure 2. PPTC7 interacts with NIX/BNIP3 and FBXL4 and is not required for FBXL4 to*
 528 *interact with CUL1 and SKP1*



529

530 **A. Analysis of the stability of the outer membrane form of PPTC7 in response to DFP**
 531 **treatment, DMOG treatment, and/or FBXL4 deficiency.**


532 **B. Analysis of the stability of the outer membrane form of endogenous PPTC7 and**
 533 **exogenous PPTC7(HA) in response to DFP treatment.**

534 **C. PPTC7 is not required for FBXL4 to interact with CUL1 or SKP1.** 293T or 293T PPTC7
 535 **KO cells were transfected with either FLAG-FBXL4 or FLAG-PPTC7. Cells were treated**

536 with MLN4924 for 24 hours where indicated. Cell lysates were immunoprecipitated with
537 anti-FLAG beads, and the immuno-precipitates were analysed by immunoblotting as
538 indicated. FBXL4 binds to CUL1 and SKP1, whereas PPTC7 binds to BNIP3 and NIX.
539 WCL = whole cell lysates.

540 D. ITC comparison of PPTC7 wild-type binding to Mg^{2+} and Mn^{2+} . The binding affinities
541 were 6.21 nM for Mn^{2+} and 237 nM for Mg^{2+} .
542 E. ITC comparison of PPTC7 wild-type binding to BNIP3 and NIX in the presence of Mn^{2+} .
543 The binding affinities were 20.1 μM for BNIP3 and 37.5 μM for NIX.
544 F. Overlay of the top 5 AlphaFold2 models of FBXL4, PPTC7, NIX with predicted aligned
545 error (PAE) plots.
546 G. *Overlay of the top 5 AlphaFold2 models of FBXL4, PPTC7, BNIP3 with PAE plots.*

547 **Figure 3. Disruption of the catalytic activity of PPTC7 does not affect BNIP3 and NIX turnover in basal**
 548 **conditions.**



549

550 **A. AlphaFold2 model of PPTC7 with active site residues indicated.** This is based on a
 551 comparison to the PBCP structure (PDB ID 6AE9). The three putative metal ions and the
 552 incoming phosphate group are modelled based on an alignment of the PPTC7 and
 553 PBCP structures.

554 B. *Binding to BNIP3 and NIX is partially preserved in the PPTC7-D78N and PPTC7-D290N*
555 *mutants.* FBXL4 KO complemented with FBXL4(HA) were transfected with PPTC7-
556 FLAG or D78N, D223N, and D290N mutants. Cells were treated with DFP for 24 hours
557 to visualise binding better. Cell lysates were immunoprecipitated with anti-FLAG beads,
558 and the immuno-precipitates were analysed by immunoblotting as shown.


559 C. *PPTC7-wildtype can dephosphorylate BNIP3 but PPTC7-D290N cannot.* Electrophoretic
560 mobility shift assays of BNIP3 using phos-tag gels were performed to assess the
561 phosphorylation status of BNIP3. Purified PPTC7 or PPTC7-D290N were incubated with
562 293T PPTC7 KO cell lysates. Wild-type PPTC7 was able to dephosphorylate BNIP3 in a
563 Mn²⁺-dependent manner as demonstrated by the loss of the upper form of BNIP3.
564 However, PPTC7-D290N was not able to dephosphorylate BNIP3 in the same
565 conditions. Lamda-phosphatase is used as a control to demonstrate that the upper band
566 of BNIP3 seen on the phos-tag gels is the phosphorylated species.

567 D. *In vitro pNPP dephosphorylation assay using purified PPTC7-wildtype and PPTC7-*
568 *D290N.* The dephosphorylation of pNPP was measured at 405 nm after a 15 minute
569 reaction. 10 mM pNPP was added to 4 μM PPTC7 in the presence or absence of either
570 MnCl₂ or MgCl₂.

571 E. *PPTC7-D290N can restore the turnover of BNIP3 and NIX to a similar extent as wild-*
572 *type PPTC7.* The PPTC7 KO cells were rescued with wild-type PPTC7-FLAG or
573 PPTC7-D78N, PPTC7-D223N or PPTC7-D290N variants. Cells were treated with
574 cycloheximide for 3 hours before harvesting. Samples were lysed, and immunoblotting
575 was performed.

576 F. *PPTC7-D290N can rescue the degradation of BNIP3 and NIX to a similar extent as wild-*
577 *type PPTC7.* NIX and BNIP3 protein levels (magenta) were monitored in PPTC7(FLAG)
578 expressing cells. To correlate NIX/BNIP3 levels with PPTC7 expression, PPTC7
579 expressing cells (green) are outlined in orange dotted lines.

580 *Supplementary Figure 3. Radical disruption of PPTC7's catalytic site interferes with its binding to*
 581 *BNIP3 and NIX.*



582

583 A. *Sequence alignment of PPTC7 orthologues with active site residues indicated.*


584 B. *Disruption of the PPTC7's active site residues from aspartate to alanine compromises its*
 585 *ability to downregulate BNIP3 and NIX. PPTC7 KO cells were transduced with PPTC7*
 586 *wild-type, PPTC7-D78A, or PPTC7-D223A/D78A. Wildtype PPTC7 rescued the turnover*
 587 *of BNIP3 and NIX, however, the D78A and D223A/D78A variants did not.*

588 C. *Aspartate to alanine mutations in PPTC7's active cannot rescue the downregulation of*
 589 *NIX by PPTC7. PPTC7 KO cells were complemented with PPTC7 or active site mutants*
 590 *and NIX levels were analysed by immunofluorescence microscopy.*

591 D. *Disruption of the PPTC7's active site residues from aspartate to alanine interferes with*
 592 *its ability to bind to BNIP3 and NIX. Cell lysates were immunoprecipitated with anti-*
 593 *FLAG beads, and the immuno-precipitates were analysed by immunoblotting as shown.*
 594 *Unlike the D78N mutant in Figure 3B, the D78A mutant is unable to bind to BNIP3 or*
 595 *NIX.*

596

Figure 4. The NIX-PPTC7 interaction is critical for NIX turnover and mitophagy suppression.



597

598 A. *AlphaFold2 prediction of the PPTC7-NIX complex*. Key residues in the PPTC7 interface
599 are highlighted in cyan.

600 B. *PPTC7-Y179D and PPTC7-N181E variants are unable to interact with BNIP3 and NIX*.
601 PPTC7(FLAG) and specified mutants were transfected into U2OS cells. Cells were

602 treated with DFP for 24 hours. Cell lysates were precipitated with anti-FLAG affinity resin
603 and the immuno-precipitates were analysed by immunoblotting.

604 C. *PPTC7-Y179D and PPTC7-N181E variants are unable to mediate the turnover of BNIP3*
605 *and NIX.* PPTC7(HA)-WT, PPTC7-Y179D or PPTC7-N181E were expressed in PPTC7
606 KO 293T cells. BNIP3 and NIX stability was assessed using a cycloheximide chase.


607 D. *AlphaFold2 prediction of the PPTC7-NIX complex.* Key residues in the NIX interface
608 including Arg147 are highlighted.

609 E. *Residues W144 and RPE₁₄₇₋₁₄₉ in NIX are critical for binding to OM-PPTC7.* PPTC7(HA)
610 was transduced into HeLa Flp-in NIX/BNIP3 double KO cells stably expressing inducible
611 FLAG-tagged NIX-WT or NIX mutants. NIX expression was induced with doxycycline for
612 24 hours. Cell lysates were immunoprecipitated with anti-FLAG beads, and the immuno-
613 precipitates were analysed by immunoblotting. The levels of NIX-W144D and NIX-
614 RPE/AAA were significantly higher than NIX-wild-type. Red asterisks mark the
615 NIX(FLAG) proteins. The different migration of the point mutants by electrophoresis
616 could be due to the change in charge of the residues or because PPTC7 is unable to
617 dephosphorylate NIX.

618 F. *NIX-W144D and NIX-RPE/AAA are stabilized in comparison to wild-type NIX.* HeLa Flp-
619 in NIX/BNIP3 double KO cells expressing FLAG-tagged NIX WT or NIX mutants were
620 subjected to a cycloheximide chase.

621 G. *Expression of hyper-stable NIX-W144D and NIX-RPE/AAA leads to an increase in basal*
622 *levels of mitophagy.* Hela Flp-In NIX knockout/ Hela Flp-In NIX/BNIP3 double knockout
623 Keima cells stably expressing NIX and NIX mutants were treated with doxycycline for 48
624 hours and mitophagy was evaluated using live-cell confocal fluorescence microscopy.
625 Mitophagy is represented as the ratio of mt-Keima 561 nm fluorescence intensity divided
626 by mt-Keima 458 nm fluorescence intensity for individual cells normalised to the
627 untreated U2OS cells. Translucent grey dots represent measurements from individual
628 cells. Colored circles represent the mean ratio from independent experiments. The
629 centre lines and bars represent the mean of the independent replicates +/- standard
630 deviation. 4 data points are outside the axis limits. P values were calculated based on
631 the mean values using a one-way ANOVA (*P<0.05, **P<0.005, ***P<0.001,
632 ****P<0.0001). N=3.

633 *Supplementary Figure 4. The NIX-PPTC7 interaction is critical for NIX turnover and mitophagy*
 634 *suppression.*



635

636 **A. Sequence alignment of BNIP3 and NIX orthologues.** Functionally relevant motifs or
 637 domains are indicated.

638 **B. PPTC7-Y179D and PPTC7-N181E variants localise to mitochondria.** Wild-type PPTC7
 639 can reduce NIX levels when expressed in PPTC7 KO cells, but PPTC7-Y179D and
 640 PPTC7-N181E cannot.

641 **C. Arg147 in NIX is critical for binding to PPTC7.** PPTC7(HA) was transduced into cell lines
 642 expressing inducible NIX mutants. NIX expression was induced with doxycycline for 24
 643 hours. Cell lysates were immunoprecipitated with anti-FLAG beads, and the immuno-
 644 precipitates were analysed by immunoblotting.

645 **D. Arg147 in NIX is critical for its turnover.** HeLa Flp-in BNIP3/NIX double KO cells
 646 expressing FLAG-tagged NIX WT or NIX binding mutants (FLAG-tagged NIX Δ144-150,
 647 NIX RPE-AAA and NIX RPE-DAA) were subjected to a cycloheximide chase.


648 **E. Expression of NIX-RPE/AAA and NIX-RPE/DAA in NIX leads to an increase in basal**

649 levels of mitophagy compared with NIX-wildtype. HeLa Flp-In NIX knockout/ HeLa Flp-In

650 BNIP3/NIX double knockout Keima cells stably expressing NIX mutants were treated
651 with doxycycline for 48 hours and mitophagy was evaluated using live-cell confocal
652 fluorescence microscopy.

653
654

Figure 5. The FBXL4-PPTC7 interaction is required for BNIP3 and NIX turnover and mitophagy suppression.



655
656
657
658

A. Alphafold2 structural modelling of FBXL4 in complex with PPTC7. Alphafold2 predicts a high confidence interaction between FBXL4 and PPTC7 centred on Met71 and Arg544 in FBXL4.


659 B. *Met71 and Arg544 in FBXL4 are involved in the interaction with PPTC7.* FBXL4
660 knockout cells were complemented with HA-tagged wild-type FBXL4, FBXL4-M71E,
661 FBXL4-R544E or FBXL4-M71E/R544E. Cells were transfected with FLAG-tagged
662 PPTC7 as indicated, lysed, and subjected to affinity purification using anti-FLAG resin.
663 WCL = whole cell lysates.

664 C. *FBXL4-M71E, FBXL4-R544E or FBXL4-M71E/R544E variants are unable to mediate*
665 *BNIP3 and NIX downregulation and destabilisation.* U2OS FBXL4 KO cells were
666 rescued with wild-type FBXL4(HA) or specified variants.

667 D. *Localization of FBXL4-M71E, FBXL4-R544E or FBXL4-M71E/R544E variants.* U2OS
668 FBXL4 KO cells expressing FBXL4(HA) wildtype or specified variants were fixed and
669 stained for HA to detect FBXL4 (in magenta) or NIX (green). NIX levels are inversely
670 correlated with the ability of FBXL4 to bind to PPTC7.

671 E. *FBXL4-M71E/R544E is less efficient than wild-type FBXL4 in mediating mitophagy*
672 *suppression.* U2OS mt-Keima cells, U2OS mt-Keima FBXL4 KO cells and FBXL4 KO
673 cells rescued with FBXL4 constructs were analyzed by confocal microscopy to quantify
674 mitophagy.

675 **Figure 6. Working model for FBXL4 and PPTC7 mediated turnover of BNIP3 and NIX for mitophagy**
676 **suppression.**



677

678 A. Model of the combination of Alphafold2 PPTC7-BNIP3-FBXL4 with the structure of
679 Skp1-Cul1-Ube2d-Ub-Nedd8 (Beok 2020, PDB ID 6TTU). PPTC7 interacts with
680 BNIP3/NIX and with FBXL4. One interpretation of our data is that PPTC7 bridges the
681 interaction between FBXL4 and BNIP3/NIX to position BNIP3/NIX substrates for
682 productive ubiquitylation by SCF-FBXL4.

683 B. *Working model for the role of PPTC7 in mitophagy suppression.* In steady-state
684 conditions, low levels of PPTC7 localize at the mitochondrial outer membrane to mediate
685 the constitutive turnover of BNIP3/NIX, and the majority of PPTC7 remains in the
686 mitochondrial matrix. PPTC7 accumulates at the mitochondria outer membrane in

687 conditions of high mitophagy such as pseudohypoxia to dampen mitophagy. PPTC7
688 accumulation on the outer membrane may be a result of active retention mechanisms or
689 defective mitochondrial import.

690

691

Methods and Materials

692

REAGENT or RESOURCE	SOURCE or REFERENCE	IDENTIFIER
Bacterial Strains		
<i>E. coli</i> DH5α	Invitrogen	18265017
<i>E. coli</i> BL21(DE3)	Merck Australia	CMC0016
Antibodies		
BNIP3 (ANa-40) mouse monoclonal	Santa Cruz Biotechnology	sc-56167
BNIP3 rabbit monoclonal	Abcam	ab109362
Cullin 1 rabbit	Invitrogen	718700
FLAG monoclonal	Sigma-Aldrich	F3165
FLAG rabbit polyclonal	Sigma-Aldrich	SAB4301135
GFP	Invitrogen	MA5-15256
HA rabbit monoclonal	Cell Signalling Technology	3724S
HDAC6	Santa Cruz Biotechnology	sc-11420
HIF1α rabbit monoclonal	Cell Signalling Technology	36169S
MTCO2 mouse monoclonal	Abcam	ab110258
MYC	Bethyl Technologies	A190-105A
NIX mouse monoclonal	Santa Cruz Technologies	sc-166332
NIX rabbit polyclonal	Cell Signalling Technology	12396
p27 mouse monoclonal	BD Biosciences	610242
PPTC7 rabbit	Novus Biologicals	NBP1-90654
Skp1	Pagano Laboratory	
TOMM20 mouse monoclonal	BD Biosciences	Clone 29 612278
HSP60		
Vinculin (VCL) mouse monoclonal	Santa Cruz Biotechnology	sc-55465
Donkey anti mouse IgG Alexa FluorTM 488	Invitrogen	A21202
Donkey anti-mouse IgG Alexa FluorTM 555	Invitrogen	A31570
Donkey anti-mouse IgG Alexa Fluor TM 647	Invitrogen	A31571
Donkey anti-rabbit IgG Alexa FluorTM 488	Invitrogen	A21026
Donkey anti-rabbit IgG Alexa FluorTM 555	Invitrogen	A31572
Donkey anti-rabbit IgG Alexa FluorTM 647	Invitrogen	A31573
Chemicals		
Benzamidine hydrochloride hydrate	Sigma Aldrich	B6506
Deoxyribonuclease I (DNase I)	Sigma Aldrich	DN25
Talon® resin	Clontech	635503
Glutathione Sepharose 4B	GE Healthcare	GEHE17-0756-0
Isopropyl β-D-1-thiogalactopyranoside	Bioline	BIO-37036
Recombinant DNA		

PPTC7-1_pLentiCRISPR v2	This paper	
PPTC7-2_pLentiCRISPR v2	This paper	
Fbxl4 CRISPR guide RNA 2_pSpCas9 BB-2A-Puro (PX459) v2.0	Nguyen-Dien	
hPPTC7_pcDNA3.1(+)-C-DYK	This paper	
hPPTC7-pcDNA3.1-FLAG	Natalie Niemi	
pLV[Exp]-Puro-EF1A>hPPTC7[NM_139283.2]/HA	This paper	
FBXL4-pcDNA3.1-3XFLAG	This paper	
D290N_hPPTC7_pcDNA3.1(+)-C-DYK	This paper	
D223N_hPPTC7_pcDNA3.1(+)-C-DYK	This paper	
D78N_hPPTC7_pcDNA3.1(+)-C-DYK	This paper	
pLV_Puro_EF1A_PPTC7_FLAG	This paper	
D78N_pLV_Puro_EF1A_PPTC7_FLAG	This paper	
D223N_pLV_Puro_EF1A_PPTC7_FLAG	This paper	
D290N_pLV_Puro_EF1A_PPTC7_FLAG	This paper	
D78A_hPPTC7_pcDNA3.1(+)-C-DYK	This paper	
D78A/D223A_hPPTC7_pcDNA3.1(+)-C-DYK	This paper	
D223A_D78A_pLV_Puro_EF1A_PPTC7_HA	This paper	
D78A_pLV_Puro_EF1A_PPTC7_HA	This paper	
K130E_hPPTC7_pcDNA3.1(+)-C-DYK	This paper	
Q128R_hPPTC7_pcDNA3.1(+)-C-DYK	This paper	
Y179D_hPPTC7_pcDNA3.1(+)-C-DYK	This paper	
N181E_hPPTC7_pcDNA3.1(+)-C-DYK	This paper	
Q128R_pLV_Puro_EF1A_PPTC7_HA	This paper	
K130E_pLV_Puro_EF1A_PPTC7_HA	This paper	
Y179D_pLV_Puro_EF1A_PPTC7_HA	This paper	
N181E_pLV_Puro_EF1A_PPTC7_HA	This paper	
NIXRPE-AAA	This paper	
NIXD140-150	This paper	
M71E_pLV_FBXL4_HA_WT_VB3	This paper	
Arg544E_pLV_FBXL4_HA_WT_VB3	This paper	
M71E and Arg544E_pLV_FBXL4_HA_WT_VB3	This paper	
pLVX TetOne BNIP3	This paper	
pLVX TetOne NIX	This paper	
Plasmid: pGEX-6P-2	Cytiva	28-9545-50
Plasmid: pGEX-6P-2 GST-PPTC7(31-304)	This study	N/A
Plasmid: pGEX-6P-2 GST-PPTC7(31-304)(D290N)	This study	N/A
Deposited Data		
SCF β TRPC (crystal structure)	RSCB Protein Data Bank	PDB ID: 6TTU
Human PPTC7 (protein sequence)	Uniprot	Q8NI37
Human FBXL4 (open reading frame)	Uniprot	Q9UKA2
Human BNIP3 (protein sequence)	Uniprot	Q12983
Human NIX (protein sequence)	Uniprot	O60238

Software		
Pymol	Schrodinger, USA.	https://pymol.org/2/
Consurf	⁴⁴	https://consurf.tau.ac.il/consurf_index.php
AlphaFold2 Multimer	^{45,46}	https://github.com/deepmind/alphafold
ColabFold and ColabFold batch	⁴⁷	https://github.com/sokrpton/ColabFold
Other		
HiLoad™ Superdex75 PG	GE Healthcare	Catalogue: 28989333

694 *CRISPR-CAS9 mediated genome editing*

695 To generate HeLa and U2OS PPTC7 KO cell lines, PPTC7-1_pLentiCRISPR V2 and PPTC7-
696 2_pLentiCRISPR V2 plasmids were generated by Genscript® based on the the following gRNA
697 sequences: TTCGTACCTAGTAATCCCAT and CGGCGACTACGGACTGGTGA, respectively.
698 The pLenti-CRISPR V2 plasmids were used to generate lentiviruses in 293T cells. HeLa or
699 U2OS cells were transduced with lentivirus, and approximately 24 hours post-transduction, cells
700 were selected with puromycin for 48 hours. Successful knockout was confirmed using
701 immunoblotting using antibodies to PPTC7. FBXL4 deficient U2OS cells (clone 2G10) have
702 been described previously¹⁸. PPTC7 deficient 293T cells have been described previously⁴⁸.

703 *Cell culture, transfection, and chemicals*

704 Cell lines were incubated at 37°C in a humidified incubator containing 5% CO₂. HeLa (ATCC
705 CCL-2), U2OS (ATCC HTB-96) and HEK293T (ATCC CRL-3216) cells were propagated in
706 Dulbecco's Modified Eagle's medium/Nutrient mixture F-12 GlutaMAX™ (DMEM/F-12; Thermo
707 Fisher Scientific) supplemented with 10% foetal bovine serum (Gibco). All cell lines were
708 regularly screened for mycoplasma contamination. Plasmid transfections were performed using
709 Lipofectamine 2000 (Thermo Fisher Scientific) according to the manufacturer's
710 recommendations. Cells were transfected with plasmid DNA using Lipofectamine 2000 (Thermo
711 Scientific) for approximately 48 h. The following chemicals from Sigma were used:
712 cycloheximide (CHX; 100 µg/ml; 66-81-9), deferiprone (DFP; 1 mM; 379409), DMOG (0.5 mM;
713 D3695) and echinomycin (10 nM; SML0477). MLN4924 (0.5 µM; 85923S) was obtained from
714 Cell Signaling Technology. MG132 (10 µM; 474787) was purchased from Merck.

715 HeLa mtKeima cell lines expressing dox-inducible FLAG-S tag NIX-wild-type and NIX mutants
716 were generated as described previously⁴⁹. Briefly, pcDNA5/FRT/TO (Thermo Fisher) constructs
717 expressing NIX or variants were co-transfected with pOG44 into HeLa-T-rex Flp-in cells
718 mtKeima cells to generate inducible cell lines using Flippase (Flp) recombination target
719 (FRT)/Flp-mediated recombination technology. Twenty-four hours post-transfection, cells were
720 selected with Hygromycin B (400 µg/ml) for approximately 10 days. To induce expression, cells
721 were treated with 0.5 µg/ml doxycycline (Sigma; 10592-13-9).

722 *Virus production and transduction*

723 Lentiviruses (pLV constructs) or retroviruses (pCHAC-mt-mKeima) were packaged in HEK293T
724 cells. The media containing lentiviral or retroviral particles were harvested 48 h later. Cells were
725 transduced with virus along with 10 µg/mL polybrene (Sigma). Following transduction, cell lines
726 were either sorted using FACS based on fluorescence (for mtKeima) or selected with puromycin
727 (for cells with pLV constructs).

728 *Biochemical techniques, immunoblotting, and co-immunoprecipitation*

729 Immunoblotting was performed as previously described¹⁸. Cultured cells were harvested and
730 lysed in SDS lysis buffer (50 mM Tris, 2% SDS) followed by heating at 95°C for 15 minutes.
731 Protein extracts were diluted in Bolt™ LDS Sample Buffer (Invitrogen™; B0008). Equal amounts
732 of protein samples were separated using BOLT pre-cast 4–12% gradient gels (Invitrogen™) and
733 transferred onto methanol-pretreated Immobilon®-P PVDF Membrane (0.45 µm pore size)
734 (Merck; IPVH00010) using BOLT gel transfer cassettes and BOLT transfer buffer (Invitrogen™;

735 BT0006). Membranes were blocked in 5% skim milk for 1 h at room temperature followed by
736 overnight incubation at 4°C with the indicated primary antibodies. Chemilumiscent detection of
737 HRP-conjugated secondary antibodies was performed using Pierce ECL Western blotting
738 substrate (Thermo Fisher Scientific; 32106) or Pierce SuperSignal West Femto Substrate
739 (Thermo Fisher Scientific; 34094) and ChemiDoc™ Imaging System (Bio-Rad). Phos-tag
740 Precast gels were purchased from Fujifilm/WAKO and run according to the manufacturer's
741 instructions. For immunoprecipitation, cellular lysis was performed using a Tris-Triton lysis
742 buffer (50 mM Tris-Cl pH 7.5, 150 mM NaCl, 10% glycerol, 1 mM EDTA, 1 mM EGTA, 5 mM
743 MgCl₂, 1 mM β-glycerophosphate, and 1% Triton), supplemented with protease inhibitor cocktail
744 (Rowe Scientific; CP2778) and PhosSTOP EASYpack Phosphatase Inhibitor Cocktail (Roche;
745 4906837001), and kept on ice for 30 minutes. Subsequently, cell lysates were centrifuged at
746 21,130 g for 10 minutes at 4°C. For immunoprecipitation of exogenously expressed FLAG-
747 tagged or HA-tagged proteins, the cell lysates were incubated with bead-conjugated FLAG
748 (Sigma; A2220) or bead-conjugated HA (Thermo Fisher Scientific; 88837) respectively, in a
749 rotating incubator for 1-2 hours at 4°C. The immunoprecipitated complexes were then washed
750 five times with Tris-Triton lysis buffer before elution with Bolt™ LDS Sample Buffer for
751 subsequent immunoblotting.

752 *Protease import protection assay*

753 Crude mitochondria were prepared by resuspending cell pellets in mitochondrial isolation buffer
754 (250 mM mannitol, 0.5 mM EGTA and 5 mM HEPES-KOH pH 7.4) followed by homogenisation
755 using a 26.5 G needle (303800, Becton Dickinson) for 10 strokes, as in ⁵⁰. The homogenate
756 was then centrifuged twice at 600 g for 10 minutes at 4 °C to remove cell debris and intact
757 nuclei. The supernatant was then centrifuged twice at 7000 g for 10 minutes at 4 °C to acquire a
758 mitochondrial pellet. The resuspended pellets were centrifuged twice at 10 000 g for 10 minutes
759 at 4 °C. Isolated mitochondria were then divided into untreated or proteinase K treated
760 conditions (10 µg/ml Proteinase K, EO0492, Life Technologies). Samples were rotated for 20
761 minutes at 4 °C. Proteinase K digestion was then blocked with 1 mM phenylmethylsulfonyl
762 fluoride (PMSF, sc-482875, Santa Cruz Biotechnology) on ice for 10 min. Samples were
763 centrifuged at 10 000 g for 10 minutes at 4 °C. Pellets were resuspended in 1X NuPAGE LDS
764 sample buffer (NP0007, Life Technologies) and analysed by immunoblotting.

765 *Protein expression and purification*

766 GST-PPTC7 (31-304) in the pGEX-6P-2 vector was transformed into BL21(DE3) cells and
767 plated on LB-Agar plates containing 0.1 mg/mL ampicillin. A single colony from this plate was
768 used to inoculate 200 mL of LB medium (containing 0.1 mg/mL ampicillin) and grown overnight
769 at 37°C with shaking at 180 rpm. The following day, 10 mL of overnight culture was used to
770 inoculate 1L of LB medium, supplemented with 0.1 mg/mL ampicillin. Cultures were grown at
771 37°C with shaking at 190 rpm until the OD₆₀₀ reached 0.9-1.0, at which point protein expression
772 was induced by adding 0.5 mM IPTG and the temperature was lowered to 20°C. Cultures
773 continued to grow overnight. Cells were harvested the following day by centrifugation at 6,200
774 rpm for 7 minutes using a Beckman JLA 8.1000 rotor. Cells were resuspended in lysis buffer (50
775 mM Tris, pH 8.0, 500 mM NaCl, 10% glycerol, benzamidine (0.1 mg/mL) and DNase (0.1
776 mg/mL) and lysed using a Cell Disruptor (Constant Systems) at 35 kPsi. The cell lysate was

777 centrifuged at 14,000 rpm for 40 minutes at 4°C using a Beckman JLA 16.250 rotor. The soluble
778 fraction was then purified by affinity chromatography using glutathione-sepharose resin. The
779 GST tag was removed from the protein by incubating the resin with PreScission protease
780 overnight at 4°C. Untagged PPTC7 was eluted the following day in lysis buffer. The elution was
781 further purified by gel filtration chromatography using a Superdex 75 (16/600) column (GE
782 Healthcare) into buffer containing 50 mM HEPES (pH 7.5), 300 mM NaCl and 2 mM β -
783 mercaptoethanol.

784 *Isothermal titration calorimetry (ITC)*

785 All ITC experiments were performed using a Microcal PEAQ-ITC instrument (Malvern) at 25°C.
786 Before performing the metal-binding experiments, PPTC7 was incubated with 1 mM EDTA and
787 then gel-filtered using a PD10 desalting column (Cytiva) to remove any bound metal ions. All
788 metal-binding experiments were performed in buffer containing 50 mM HEPES (pH 7.5), 200
789 mM NaCl and 2 mM β -mercaptoethanol. In these experiments, 150 μ M MnCl₂ or MgCl₂ was
790 titrated into 15 μ M PPTC7. Experiments to test the binding of PPTC7 to BNIP3 and NIX
791 peptides were performed in buffer containing 50 mM HEPES (pH 7.5), 300 mM NaCl, 10 mM
792 MnCl₂ and 2 mM β -mercaptoethanol. In all experiments, 500 μ M of peptide was titrated into 25
793 μ M PPTC7. The dissociation constant (K_D), enthalpy of binding (Δ H) and stoichiometry (N) were
794 calculated using the MicroCal PEAQ-ITC software.

795 *pNPP phosphatase assay*

796 The generic phosphatase substrate para-nitrophenyl phosphate (pNPP) was used to determine
797 the phosphatase activity of recombinant PPTC7 wild-type and PPTC7-D290N mutant. 10 mM
798 pNPP (New England Biolabs) was added to 4 μ M PPTC7 in the presence or absence of either 5
799 mM MnCl₂ or 5 mM MgCl₂. All reactions were carried out in buffer containing 50 mM HEPES
800 (pH 7.5), 200 mM NaCl and 2 mM β -mercaptoethanol, in a total volume of 100 μ L. The reaction
801 was incubated for 15 minutes at room temperature before measuring the absorbance at 405 nm
802 using an Infinite M1000 Pro plate reader (Tecan).

803 *Protein structural prediction, modelling and visualisation*

804 All protein models were generated using AlphaFold2 Multimer^{45,46} implemented in the Colabfold
805 interface available on the Google Colab platform⁴⁷. For each modelling experiment ColabFold
806 was executed using default settings where multiple sequence alignments were generated with
807 MMseqs2⁵¹. For all final models displayed in this manuscript, structural relaxation of peptide
808 geometry was performed with AMBER⁵². For all modelling experiments, we assessed (i) the
809 prediction confidence measures (pLDDT and interfacial iPTM scores), (ii) the plots of the
810 predicted alignment errors (PAE) and (iii) backbone alignments of the final structures. The
811 model of PPTC7 and NIX bound to the SCF^{FBXL4} complex was constructed in two steps. Firstly,
812 the trimeric PPTC7–NIX–FBXL4 complex was predicted with AlphaFold2 as described above.
813 This was then aligned to the structure of SCF ^{β TRCP} consisting of the proteins β TRCP–Skp1–
814 Cul1–Rbx1–Ube2d–Nedd8–Ub (PDB ID 6TTU)⁵³. All structural images were made with Pymol
815 (Schrodinger, USA; <https://pymol.org/2/>).

816 *Indirect immunofluorescence staining and mtKeima assay*

817 Cells grown as monolayers on coverslips were fixed with ice-cold methanol. Cells were blocked
818 with 2% BSA in PBS. Cells were then sequentially labelled with primary antibodies for 1 h,
819 followed by the species-specific secondary antibodies for 1 h. Coverslips were mounted on
820 glass microscope slides using Prolong Diamond Antifade Mountant (Thermo Fisher Scientific;
821 P36965). Images were acquired using either a DeltaVision Elite inverted microscope system
822 (GE Healthcare) or a using a $\times 60/1.4$ NA Oil PSF Objective from Olympus or Zeiss LSM900 Fast
823 AiryScan2 Confocal microscope with a $63\times$ C-Plan Apo NA 1.4 oil-immersion objective.
824 DeltaVision images were processed using the Softworx deconvolution algorithm whereas
825 Airyscan images were processed using ZEN Blue 3D software (version 3.4).

826 The mt-Keima assay was performed as previously described (Sun et al., 2017). A Leica DMI8
827 SP8 Inverted confocal microscope equipped with a $63\times$ Plan Apochromatic objective and
828 environmental chamber (set to 5% CO₂ and 37°C) was used to capture images. Quantitative
829 analysis of mitophagy with mt-Keima was performed using Image J/Fiji software. Individual cells
830 were isolated from the field of view by creating regions of interest (ROI). The chosen ROI were
831 then cropped and separated into distinct channels before undergoing threshold processing. The
832 fluorescence intensity of mt-Keima at 561 nm (indicating lysosomal signal) and 458 nm
833 (indicating mitochondrial signal) at the single-cell level was measured, and the ratio of 561 nm
834 to 458 nm was calculated. Three biological replicates were performed for each experiment, with
835 >50 cells analyzed per condition for each repeat.

836 *Statistical Analysis*

837 GraphPad Prism 9.0 software was used to perform statistical comparisons. The centre line and
838 error bars on the graphs represent the mean and standard deviation of normalised biologically
839 independent replications. Unless otherwise noted, three or more biologically independent
840 replications for used for statistical comparisons. No blinding or randomisation was incorporated
841 into the experimental design. *P* values greater than 0.05 were considered non-significant.

842 **Acknowledgements**

843 We thank Natalie Niemi and David Pagliarini for helpful discussions, the FLAG-PPTC7 plasmid,
844 and the PPTC7 KO 293T cells. Imaging was performed at the Microscopy and Image Analysis
845 Facility in the School of Biomedical Sciences at the University of Queensland. Lentiviruses were
846 produced by the University of Queensland (UQ)-Viral Vector Core. This work was supported by
847 the Australian National Health and Medical Research Council (APP1183915 and APP1136021),
848 a Brain Foundation Research grant (2020), a Mito Foundation Incubator Grant (2022), Mito
849 Foundation Research Fellowship to P.K. and a Mito Foundation Scholarship Top-up to K.L.K.
850 and an Australian Research Council Future Fellowship (FT180100172) to J.K.P. B.M.C is
851 supported by an Australian NHMRC Investigator Grant (APP2016410).

852 **References**

853

854

855 1. Uoselis, L., Nguyen, T.N., and Lazarou, M. (2023). Mitochondrial degradation:
856 Mitophagy and beyond. *Mol Cell* 83, 3404-3420. 10.1016/j.molcel.2023.08.021.

857 2. Onishi, M., Yamano, K., Sato, M., Matsuda, N., and Okamoto, K. (2021). Molecular
858 mechanisms and physiological functions of mitophagy. *EMBO J* 40, e104705.
859 10.15252/embj.2020104705.

860 3. Marinkovic, M., and Novak, I. (2021). A brief overview of BNIP3L/NIX receptor-mediated
861 mitophagy. *FEBS Open Bio* 11, 3230-3236. 10.1002/2211-5463.13307.

862 4. Hanna, R.A., Quinsay, M.N., Orogo, A.M., Giang, K., Rikka, S., and Gustafsson, A.B.
863 (2012). Microtubule-associated protein 1 light chain 3 (LC3) interacts with Bnip3 protein
864 to selectively remove endoplasmic reticulum and mitochondria via autophagy. *J Biol
865 Chem* 287, 19094-19104. 10.1074/jbc.M111.322933.

866 5. Rogov, V.V., Suzuki, H., Marinkovic, M., Lang, V., Kato, R., Kawasaki, M., Buljubasic,
867 M., Sprung, M., Rogova, N., Wakatsuki, S., et al. (2017). Phosphorylation of the
868 mitochondrial autophagy receptor Nix enhances its interaction with LC3 proteins. *Sci
869 Rep* 7, 1131. 10.1038/s41598-017-01258-6.

870 6. Zhao, J.F., Rodger, C.E., Allen, G.F.G., Weidlich, S., and Ganley, I.G. (2020).
871 HIF1alpha-dependent mitophagy facilitates cardiomyoblast differentiation. *Cell Stress* 4,
872 99-113. 10.15698/cst2020.05.220.

873 7. Bellot, G., Garcia-Medina, R., Gounon, P., Chiche, J., Roux, D., Pouyssegur, J., and
874 Mazure, N.M. (2009). Hypoxia-induced autophagy is mediated through hypoxia-inducible
875 factor induction of BNIP3 and BNIP3L via their BH3 domains. *Mol Cell Biol* 29, 2570-
876 2581. 10.1128/MCB.00166-09.

877 8. Allen, G.F., Toth, R., James, J., and Ganley, I.G. (2013). Loss of iron triggers
878 PINK1/Parkin-independent mitophagy. *EMBO Rep* 14, 1127-1135.
879 10.1038/embor.2013.168.

880 9. Novak, I., Kirkin, V., McEwan, D.G., Zhang, J., Wild, P., Rozenknop, A., Rogov, V., Lohr,
881 F., Popovic, D., Occhipinti, A., et al. (2010). Nix is a selective autophagy receptor for
882 mitochondrial clearance. *EMBO Rep* 11, 45-51. 10.1038/embor.2009.256.

883 10. Sandoval, H., Thiagarajan, P., Dasgupta, S.K., Schumacher, A., Prchal, J.T., Chen, M.,
884 and Wang, J. (2008). Essential role for Nix in autophagic maturation of erythroid cells.
885 *Nature* 454, 232-235. 10.1038/nature07006.

886 11. Schweers, R.L., Zhang, J., Randall, M.S., Loyd, M.R., Li, W., Dorsey, F.C., Kundu, M.,
887 Opferman, J.T., Cleveland, J.L., Miller, J.L., and Ney, P.A. (2007). NIX is required for
888 programmed mitochondrial clearance during reticulocyte maturation. *Proc Natl Acad Sci
889 U S A* 104, 19500-19505. 10.1073/pnas.0708818104.

890 12. Ordureau, A., Kraus, F., Zhang, J., An, H., Park, S., Ahfeldt, T., Paulo, J.A., and Harper,
891 J.W. (2021). Temporal proteomics during neurogenesis reveals large-scale proteome
892 and organelle remodeling via selective autophagy. *Mol Cell* 81, 5082-5098 e5011.
893 10.1016/j.molcel.2021.10.001.

894 13. Esteban-Martinez, L., Sierra-Filardi, E., McGreal, R.S., Salazar-Roa, M., Marino, G.,
895 Seco, E., Durand, S., Enot, D., Grana, O., Malumbres, M., et al. (2017). Programmed
896 mitophagy is essential for the glycolytic switch during cell differentiation. *EMBO J* 36,
897 1688-1706. 10.15252/embj.201695916.

898 14. Lampert, M.A., Orogo, A.M., Najor, R.H., Hammerling, B.C., Leon, L.J., Wang, B.J., Kim,
899 T., Sussman, M.A., and Gustafsson, A.B. (2019). BNIP3L/NIX and FUNDC1-mediated
900 mitophagy is required for mitochondrial network remodeling during cardiac progenitor
901 cell differentiation. *Autophagy* 15, 1182-1198. 10.1080/15548627.2019.1580095.

902 15. Simpson, C.L., Tokito, M.K., Uppala, R., Sarkar, M.K., Gudjonsson, J.E., and Holzbaur,
903 E.L.F. (2021). NIX initiates mitochondrial fragmentation via DRP1 to drive epidermal
904 differentiation. *Cell Rep* 34, 108689. 10.1016/j.celrep.2021.108689.

905 16. Sowter, H.M., Ratcliffe, P.J., Watson, P., Greenberg, A.H., and Harris, A.L. (2001). HIF-
906 1-dependent regulation of hypoxic induction of the cell death factors BNIP3 and NIX in
907 human tumors. *Cancer Res* 61, 6669-6673.

908 17. Tracy, K., Dibling, B.C., Spike, B.T., Knabb, J.R., Schumacker, P., and Macleod, K.F.
909 (2007). BNIP3 is an RB/E2F target gene required for hypoxia-induced autophagy. *Mol
910 Cell Biol* 27, 6229-6242. 10.1128/MCB.02246-06.

911 18. Nguyen-Dien, G.T., Kozul, K.L., Cui, Y., Townsend, B., Kulkarni, P.G., Ooi, S.S., Marzio,
912 A., Carrodus, N., Zuryn, S., Pagano, M., et al. (2023). FBXL4 suppresses mitophagy by
913 restricting the accumulation of NIX and BNIP3 mitophagy receptors. *EMBO J* 42,
914 e112767. 10.15252/embj.2022112767.

915 19. Elcocks, H., Brazel, A.J., McCarron, K.R., Kaulich, M., Husnjak, K., Mortiboys, H.,
916 Clague, M.J., and Urbe, S. (2023). FBXL4 ubiquitin ligase deficiency promotes
917 mitophagy by elevating NIX levels. *EMBO J* 42, e112799. 10.15252/embj.2022112799.

918 20. Chen, Y., Jiao, D., Liu, Y., Xu, X., Wang, Y., Luo, X., Saiyin, H., Li, Y., Gao, K., Chen, Y.,
919 et al. (2023). FBXL4 mutations cause excessive mitophagy via BNIP3/BNIP3L
920 accumulation leading to mitochondrial DNA depletion syndrome. *Cell Death Differ* 30,
921 2351-2363. 10.1038/s41418-023-01205-1.

922 21. Cao, Y., Zheng, J., Wan, H., Sun, Y., Fu, S., Liu, S., He, B., Cai, G., Cao, Y., Huang, H.,
923 et al. (2023). A mitochondrial SCF-FBXL4 ubiquitin E3 ligase complex degrades BNIP3
924 and NIX to restrain mitophagy and prevent mitochondrial disease. *EMBO J* 42, e113033.
925 10.15252/embj.2022113033.

926 22. Alsina, D., Lytovchenko, O., Schab, A., Atanassov, I., Schober, F.A., Jiang, M.,
927 Koolmeister, C., Wedell, A., Taylor, R.W., Wredenberg, A., and Larsson, N.G. (2020).
928 FBXL4 deficiency increases mitochondrial removal by autophagy. *EMBO Mol Med* 12,
929 e11659. 10.15252/emmm.201911659.

930 23. Bonnen, P.E., Yarham, J.W., Besse, A., Wu, P., Faqeih, E.A., Al-Asmari, A.M., Saleh,
931 M.A., Eyaid, W., Hadeel, A., He, L., et al. (2013). Mutations in FBXL4 cause
932 mitochondrial encephalopathy and a disorder of mitochondrial DNA maintenance. *Am J
933 Hum Genet* 93, 471-481. 10.1016/j.ajhg.2013.07.017.

934 24. Gai, X., Ghezzi, D., Johnson, M.A., Biagusch, C.A., Shamseldin, H.E., Haack, T.B.,
935 Reyes, A., Tsukikawa, M., Sheldon, C.A., Srinivasan, S., et al. (2013). Mutations in
936 FBXL4, encoding a mitochondrial protein, cause early-onset mitochondrial
937 encephalomyopathy. *Am J Hum Genet* 93, 482-495. 10.1016/j.ajhg.2013.07.016.

938 25. Guo, X., Niemi, N.M., Hutchins, P.D., Condon, S.G.F., Jochem, A., Ulbrich, A., Higbee,
939 A.J., Russell, J.D., Senes, A., Coon, J.J., and Pagliarini, D.J. (2017). Ptc7p
940 Dephosphorylates Select Mitochondrial Proteins to Enhance Metabolic Function. *Cell
941 Rep* 18, 307-313. 10.1016/j.celrep.2016.12.049.

942 26. Niemi, N.M., Wilson, G.M., Overmyer, K.A., Vogtle, F.N., Myketin, L., Lohman, D.C.,
943 Schueler, K.L., Attie, A.D., Meisinger, C., Coon, J.J., and Pagliarini, D.J. (2019). Ptc7 is
944 an essential phosphatase for promoting mammalian mitochondrial metabolism and
945 biogenesis. *Nat Commun* 10, 3197. 10.1038/s41467-019-11047-6.

946 27. Pagliarini, D.J., Calvo, S.E., Chang, B., Sheth, S.A., Vafai, S.B., Ong, S.E., Walford,
947 G.A., Sugiana, C., Boneh, A., Chen, W.K., et al. (2008). A mitochondrial protein
948 compendium elucidates complex I disease biology. *Cell* 134, 112-123.
949 10.1016/j.cell.2008.06.016.

950 28. Luck, K., Kim, D.K., Lambourne, L., Spirohn, K., Begg, B.E., Bian, W., Brignall, R.,
951 Cafarelli, T., Campos-Laborie, F.J., Charlotteaux, B., et al. (2020). A reference map of
952 the human binary protein interactome. *Nature* 580, 402-408. 10.1038/s41586-020-2188-
953 x.

954 29. Huttlin, E.L., Bruckner, R.J., Paulo, J.A., Cannon, J.R., Ting, L., Baltier, K., Colby, G.,
955 Gebreab, F., Gygi, M.P., Parzen, H., et al. (2017). Architecture of the human interactome

956 defines protein communities and disease networks. *Nature* 545, 505-509.
957 10.1038/nature22366.

958 30. Huttlin, E.L., Bruckner, R.J., Navarrete-Perea, J., Cannon, J.R., Baltier, K., Gebreab, F.,
959 Gygi, M.P., Thorne, A., Zarraga, G., Tam, S., et al. (2021). Dual proteome-scale
960 networks reveal cell-specific remodeling of the human interactome. *Cell* 184, 3022-3040
961 e3028. 10.1016/j.cell.2021.04.011.

962 31. Niemi, N.M., Serrano, L.R., Muehlbauer, L.K., Balnis, C.E., Wei, L., Smith, A.J., Kozul,
963 K.L., Forny, M., Connor, O.M., Rashan, E.H., et al. (2023). PPTC7 maintains
964 mitochondrial protein content by suppressing receptor-mediated mitophagy. *Nat
965 Commun* 14, 6431. 10.1038/s41467-023-42069-w.

966 32. Niemi, N.M., Serrano, L.R., Muehlbauer, L.K., Balnis, C., Kozul, K.L., Rashan, E.H.,
967 Shishkova, E., Schueler, K.L., Keller, M.P., Attie, A.D., et al. (2023). Pptc7 maintains
968 mitochondrial protein content by suppressing receptor-mediated mitophagy. *bioRxiv*
969 10.1101/2023.02.28.530351.

970 33. Rhee, H.W., Zou, P., Udeshi, N.D., Martell, J.D., Mootha, V.K., Carr, S.A., and Ting, A.Y.
971 (2013). Proteomic mapping of mitochondria in living cells via spatially restricted
972 enzymatic tagging. *Science* 339, 1328-1331. 10.1126/science.1230593.

973 34. Stojanovski, D., Pfanner, N., and Wiedemann, N. (2007). Import of proteins into
974 mitochondria. *Methods Cell Biol* 80, 783-806. 10.1016/S0091-679X(06)80036-1.

975 35. Liu, X., Chai, J., Ou, X., Li, M., and Liu, Z. (2019). Structural Insights into Substrate
976 Selectivity, Catalytic Mechanism, and Redox Regulation of Rice Photosystem II Core
977 Phosphatase. *Mol Plant* 12, 86-98. 10.1016/j.molp.2018.11.006.

978 36. Bryant, P., Pozzati, G., and Elofsson, A. (2022). Improved prediction of protein-protein
979 interactions using AlphaFold2. *Nat Commun* 13, 1265. 10.1038/s41467-022-28865-w.

980 37. Sun, Y., Cao, Y., Wan, H., Memetimin, A., Cao, Y., Li, L., Wu, C., Wang, M., Chen, S.,
981 Li, Q., et al. (2024). A mitophagy sensor PPTC7 controls BNIP3 and NIX degradation to
982 regulate mitochondrial mass. *Mol Cell* 84, 327-344 e329. 10.1016/j.molcel.2023.11.038.

983 38. Hao, B., Zheng, N., Schulman, B.A., Wu, G., Miller, J.J., Pagano, M., and Pavletich, N.P.
984 (2005). Structural basis of the Cks1-dependent recognition of p27(Kip1) by the
985 SCF(Skp2) ubiquitin ligase. *Mol Cell* 20, 9-19. 10.1016/j.molcel.2005.09.003.

986 39. Poole, L.P., Bock-Hughes, A., Berardi, D.E., and Macleod, K.F. (2021). ULK1 promotes
987 mitophagy via phosphorylation and stabilization of BNIP3. *Sci Rep* 11, 20526.
988 10.1038/s41598-021-00170-4.

989 40. He, Y.L., Li, J., Gong, S.H., Cheng, X., Zhao, M., Cao, Y., Zhao, T., Zhao, Y.Q., Fan, M.,
990 Wu, H.T., et al. (2022). BNIP3 phosphorylation by JNK1/2 promotes mitophagy via
991 enhancing its stability under hypoxia. *Cell Death Dis* 13, 966. 10.1038/s41419-022-
992 05418-z.

993 41. Marinkovic, M., Sprung, M., and Novak, I. (2021). Dimerization of mitophagy receptor
994 BNIP3L/NIX is essential for recruitment of autophagic machinery. *Autophagy* 17, 1232-
995 1243. 10.1080/15548627.2020.1755120.

996 42. Yuan, Y., Zheng, Y., Zhang, X., Chen, Y., Wu, X., Wu, J., Shen, Z., Jiang, L., Wang, L.,
997 Yang, W., et al. (2017). BNIP3L/NIX-mediated mitophagy protects against ischemic
998 brain injury independent of PARK2. *Autophagy* 13, 1754-1766.
999 10.1080/15548627.2017.1357792.

1000 43. Kuchay, S., Duan, S., Schenkein, E., Peschiaroli, A., Saraf, A., Florens, L., Washburn,
1001 M.P., and Pagano, M. (2013). FBXL2- and PTPL1-mediated degradation of p110-free
1002 p85beta regulatory subunit controls the PI(3)K signalling cascade. *Nat Cell Biol* 15, 472-
1003 480. 10.1038/ncb2731.

1004 44. Ashkenazy, H., Abadi, S., Martz, E., Chay, O., Mayrose, I., Pupko, T., and Ben-Tal, N.
1005 (2016). ConSurf 2016: an improved methodology to estimate and visualize evolutionary

1006 conservation in macromolecules. *Nucleic Acids Res* 44, W344-350.
1007 10.1093/nar/gkw408.

1008 45. Jumper, J., Evans, R., Pritzel, A., Green, T., Figurnov, M., Ronneberger, O.,
1009 Tunyasuvunakool, K., Bates, R., Zidek, A., Potapenko, A., et al. (2021). Highly accurate
1010 protein structure prediction with AlphaFold. *Nature* 596, 583-589. 10.1038/s41586-021-
1011 03819-2.

1012 46. Evans, R., O'Neill, M., Pritzel, A., Antropova, N., Senior, A., Green, T., Žídek, A., Bates,
1013 R., Blackwell, S., Yim, J., et al. (2022). Protein complex prediction with AlphaFold-
1014 Multimer. *bioRxiv*, 2021.2010.2004.463034. 10.1101/2021.10.04.463034.

1015 47. Mirdita, M., Schutze, K., Moriwaki, Y., Heo, L., Ovchinnikov, S., and Steinegger, M.
1016 (2022). ColabFold: making protein folding accessible to all. *Nat Methods* 19, 679-682.
1017 10.1038/s41592-022-01488-1.

1018 48. Meyer, J.G., Niemi, N.M., Pagliarini, D.J., and Coon, J.J. (2020). Quantitative shotgun
1019 proteome analysis by direct infusion. *Nat Methods* 17, 1222-1228. 10.1038/s41592-020-
1020 00999-z.

1021 49. Pagan, J.K., Marzio, A., Jones, M.J., Saraf, A., Jallepalli, P.V., Florens, L., Washburn,
1022 M.P., and Pagano, M. (2015). Degradation of Cep68 and PCNT cleavage mediate
1023 Cep215 removal from the PCM to allow centriole separation, disengagement and
1024 licensing. *Nat Cell Biol* 17, 31-43. 10.1038/ncb3076.

1025 50. Adriaenssens, E., Asselbergh, B., Rivera-Mejias, P., Bervoets, S., Vendredy, L., De
1026 Winter, V., Spaas, K., de Rycke, R., van Isterdael, G., Impens, F., et al. (2023). Small
1027 heat shock proteins operate as molecular chaperones in the mitochondrial
1028 intermembrane space. *Nat Cell Biol* 25, 467-480. 10.1038/s41556-022-01074-9.


1029 51. Mirdita, M., Steinegger, M., and Soding, J. (2019). MMseqs2 desktop and local web
1030 server app for fast, interactive sequence searches. *Bioinformatics* 35, 2856-2858.
1031 10.1093/bioinformatics/bty1057.

1032 52. Hornak, V., Abel, R., Okur, A., Strockbine, B., Roitberg, A., and Simmerling, C. (2006).
1033 Comparison of multiple Amber force fields and development of improved protein
1034 backbone parameters. *Proteins* 65, 712-725. 10.1002/prot.21123.

1035 53. Baek, K., Krist, D.T., Prabu, J.R., Hill, S., Klügel, M., Neumaier, L.-M., von Gronau, S.,
1036 Kleiger, G., and Schulman, B.A. (2020). NEDD8 nucleates a multivalent cullin-RING-
1037 UBE2D ubiquitin ligation assembly. *Nature* 578, 461-466. 10.1038/s41586-020-2000-y.

1038

Figure 1. PPTC7 and FBXL4 coordinate the turnover of BNIP3 and NIX mitophagy receptors to suppress mitophagy



Supplementary Figure 1. PPTC7 and FBXL4 coordinate the turnover of BNIP3 and NIX mitophagy receptors to suppress mitophagy






Figure 2. A population of PPTC7 localises to the mitochondria outer membrane to interact with BNIP3 and NIX and FBXL4


A




D




B




E




C




F





G





Supplementary Figure 2. PPTC7 interacts with NIX/BNIP3 and FBXL4 and is not required for FBXL4 to interact with CUL1 or SKP1





B




F



G



D



E






Figure 3. BNIP3 and NIX turnover is not affected by disruption of PPTC7 catalytic activity.


A




B




C




D



E



F



Supplementary Figure 3. Radical disruption of catalytic site in PPTC7 with alanine substitutions eliminates BNIP3 and NIX

A

bioRxiv preprint doi: <https://doi.org/10.1101/2024.02.23.581814>; this version posted February 24, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license.

```

D4A520_RAT 232 MPDYMILQELKKLKLNSNYESIORTARSIAEQAHLELAYDPNIMSPPAQFACDNGLNVRGGKPDDITVLLSIVAEYTD
S1BBSW5_BOVIN 232 MPDYMILQELKKLKLNSNYESIOQTARSIAEQAHLELAYDPNIMSPPAQFACDNGLNVRGGKPDDITVLLSIVAEYTD
PPTC7_MOUSE 235 MPDYMILQELKKLKLNSNYESIORTARSIAEQAHLELAYDPNIMSPPAQFACDNGLNVRGGKPDDITVLLSIVAEYTD
PPTC7_HUMAN 229 MPDYMILQELKKLKLNSNYESIOQTARSIAEQAHLELAYDPNIMSPPAQFACDNGLNVRGGKPDDITVLLSIVAEYTD
PPTC7_DANRE 222 MPDYMILQELKKLKLNTNYESIOQTAKSIAEQAHLELAYDPNIMSPPAQFACDNGLNVRGGKPDDITVLLSIVAEYTD
PPTC7_XENLA 222 MPDYMILQELKKLKLNTNYESIOQTARSIAEQAHLELAYDPNIMSPPAQFACDNGLNVRGGKPDDITVLLSIVAEYTD
O18183_CASBL 260 LSEQQVQLDQLKAL.DAGKSNVECVCNAL.ATARRLAFDSKHNAPFPMKAREHGFLAPGGKPDDITVLLSIVAEYTD
consensus>50 #p#y#!=L#E#LKKLKL#NYESI#OQTARSIA#EQ#A#H#E#LAYDPNIM#SPPAQFA#C#DNGL#NVRGGKPDDITVLL#SIVAEYTD

```

★ Active site residues

B

0

1







Figure 4. The NIX/BNIP3-PPTC7 interaction is critical for NIX/BNIP3 turnover and mitophagy suppression.


A




B




C




D





F



E



G



Supplement Figure 4.

A

	40	50	60	70	80	90
Q12983 BNIP3_HUMAV S I Y N G D M E K I L L D A Q H E S G R S S S K S S . H C D S P P R S Q T P Q D T N R A S E T D T H S I G E K N					
Q55003 BNIP3_MOUSV S I Y N G D M E K I L L D A Q H E S G R S S S K S S . H C D S P P R S Q T P Q D T N R A . E I D S H S F G E K N					
AOA8M2BKA1 AOA8M2	Q S A S T A P S G D L E K M L L D A Q H E S G R S S S R G S L P C D S P P R S Q T P L H L C R G S E V . H S S G E K N					
Q60238 BNI3L_HUMA	P S S S S I H N G D M E K I L L D A Q H E S G Q S S S R . . . G S H C D S P S P Q E D G Q I M F D V E M H T S R D H					
Q9Z2F7 BNI3L_MOUS	P S S S S S I H N G D M E K I L L D A Q H E S G Q S S S R . . . G S H C D S P S P Q E D G Q I M F D V E M H T S R D H					
Q58EQ7 Q58EQ7_DAN	P S S S S S I H N G D M E K I L L D A Q H E S S R S N S S . . . C D S P P R P H S P Q D E G Q I I F D V D . T R R D .					
Q8IPU7 Q8IPU7_DRO	T P L P F N N G E E Y L R L L R E A Q R E S N Q S S R R V V . . . S L A S S R R D T P R D S P K S P P N S P Q S E L C P D					
<i>consensus > 70</i>s i . n g # m e k i l l # A Q h E S g . S s s s . . . r s . . . P q d					

bioRxiv preprint doi: <https://doi.org/10.1101/2024.02.23.581814>; this version posted February 24, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license.

Sequence alignment of BNIP3_HUMA and BNIP3_MOUS. The alignment shows identical amino acids in blue, conservative substitutions in green, and non-conservative substitutions in red. A conserved region is highlighted with an orange box. The alignment is numbered 100, 110, 120, 130, and 140 along the top.

	100	110	120	130	140
Q12983 BNIP3_HUMA	S Q S E E D D I E R R K E V E S I L K K N S D W I W D W S S R P . . . E N I P P K E F L F K H P K R T A T L S M R				
O55003 BNIP3_MOUS	S T L S E E D Y I E R R R E V E S I L K K N S D W I W D W S S R P . . . E N I P P K E F L F K H P K R T A T L S M R				
A0A8M2BKA1 A0A8M2	S Q S E E D Y I E R R K E V E I L M K K N A D W I W D W S S R P . . . E N L P P K E F L I R H P K R S S T L S M R				
O60238 BNI3L_HUMA	S Q S E E E V V E G E K E V E . A L K K S A D W V S D W S S R P . . . E N I P P K E F H F R H P K R S V S L S M R				
Q9Z2F7 BNI3L_MOUS	S Q S E E E V V E G E K E V E . A L K K S A D W V S D W S S R P . . . E N I P P K E F H F R H P K R A A S L S M R				
Q58EQ7 Q58EQ7_DAN	S Q E E E V M E K I R D D . I L M K D S D R M A D W S S R P . . . E N I P P K E F H F R H P R R S V T L S M R				
Q8IPU7 Q8IPU7_DRO	D E L R N V Y I N Y W T K G G D K Q N A G N E D W L K N W N Q P P S S W N I E D S S R D A G D E G E K K K T N T G Y S I				
consensus > 70	s . . s # e d . . e . . k e v # . . l k k n . D w i . # W s s r p . . . E N I P P K E F H F R H P K R S V S L S M R				

Sequence alignment of BNIP3 variants across species (Q12983, Q55003, Q0A8M2, Q60238, Q9Z2F7, Q58EQ7, Q8IPU7) and a consensus sequence. The alignment highlights the LC3-interacting region (green), BH3 sequence (red), mitochondrial targeting (orange), and PPTC (yellow). Positions 150 to 190 are shown. A consensus sequence is provided at the bottom.

	150	160	170	180	190
Q12983 BNIP3_HUMA	NT S V	M K K G G I F S A E F L K V F L	F S L L L S H L L A I	G L G I Y I G R R L T T	S T S T F . .
Q55003 BNIP3_MOUSE	NT S V	M K K G G I F S A D F L K V F L	P S L L L S H L L A I	G L G I Y I G R R L T T	S T S T F . .
Q0A8M2BKA1 Q0A8M2	NT S V	M K K G G I F S A E F L K V F L	P S L V L S H I L A V	G L G V Y I G R R F T A S G F T . .	
Q60238 BNI3L_HUMA	K S G A	M K K G G I F S A E F L K V F I	P S L F L S H V L A L	G L G I Y I G K R L S T P S A S T Y . .	
Q9Z2F7 BNI3L_MOUSE	K S G A	M K K G G I F S A E F L K V F I	P S L F L S H V L A L	G L G I Y I G K R L S T P S A S T Y . .	
Q58EQ7 Q58EQ7_DAN	K T G A	M K K G G I F S A E F L K V F I	P S L L L S H I L V L	G L G V Y I G K R L T T P P A S S I . .	
Q8IPU7 Q8IPU7_DRO	R L K R	L G S N S L F S R E I L Y S L	L V T N V L S I L L G A G F G L W L S K R G I L L T R V V I D		
consensus > 70	\$ k k g g i F S a # f l k v f . p s l . L S h . L a . G l G i y i g . R l t			

- LC3-interacting region (LIR)
- BH3 sequence
- mitochondrial membrane anchor
- PPTC7-interaction region

3

D

WT-HA
A(PPTC7)
IX)
C7)

BNIP3/NIX DKO

		NIX WT			NIX R147D			NIX RPE-AAA			NIX RPE-DAA			(hrs) CHX
		0	4	8	0	4	8	0	4	8	0	4	8	
50 -	FLAG (NIX)													
25 -	p27													
	VCL													

Figure 5. The FBXL4-PPTC7 interaction is critical for mitophagy receptor turnover and mitophagy suppression.





Figure 6. Model for mitophagy suppression by PPTC7.

A



B

